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ABSTRACT 
Irritable bowel syndrome (IBS) affects more than one in ten individuals worldwide and is the 
most common cause of gut illness. It is classified according to the symptom-based Rome 
criteria as a functional gastrointestinal disorder (FGID) characterized by recurrent abdominal 
pain or discomfort accompanied with altered bowel habits (diarrhea, constipation or both). 
Although the research interest in IBS has grown considerably lately and several contributing 
factors are being recognized, the etiology of IBS is still far from understood. Hence, there is 
no effective cure and no established biomarkers, and current therapeutic options can only be 
directed towards symptom amelioration. IBS significantly reduces peoples’ quality of life and 
working ability, and has important socioeconomic consequences, posing a considerable 
burden both on the affected individual and the society at large. Therefore, there is an urgent 
need for improved understanding of this common gastrointestinal disorder. 
A heritable component in IBS has been demonstrated although inadequately studied; hence 
not much is known about the specific genetic architecture of IBS. Through focused genetic 
research, we strive to gain novel insight into the pathophysiology of IBS. Eventually, these 
studies will contribute to shifting the paradigm from symptom-based definitions to a 
molecular re-classification of patients, for clinical	  translation	  and	  post-­‐genomic	  approaches	  to	  stratified	  medicine	  in	  IBS.	  
The overall aim of this thesis was therefore to identify, validate and functionally characterize 
genetic factors predisposing to IBS and associated gastrointestinal symptoms. The first three 
papers included in this thesis are hypothesis- or pathway-driven candidate-gene studies 
investigating the role of specific genes in IBS predisposition, while the fourth paper is an 
important step in our broader approach to using large general population-based studies for 
IBS gene-hunting efforts.  
In paper I, we showed that genetic variation in the NPSR1 gene influences children’s 
predisposition to recurrent abdominal pain (RAP), the cardinal symptom of IBS and related 
FGIDs. The NPSR1 gene encodes the neuropeptide S (NPS) receptor, and previous evidence 
suggests its signaling to influence functions along the brain-gut axis, including mucosal 
immune activity, secretion of other neuropeptides and gut hormones, pain perception, and gut 
motor and sensory functions.  
In paper II we aimed to investigate the role of ion channel genes in IBS risk. By genotyping 
a Swedish case-control cohort for four genes that showed nominal significance in our 
previously published pilot genome-wide association study (GWAS) of IBS, we could provide 
evidence of association for the transient receptor potential cation channel gene TRPM8 (the 
‘cold and menthol receptor’). TRPM8 polymorphisms showed significant association with 
constipation-predominant IBS subtypes (IBS-C/M), and risk alleles further correlated with 
harder stool consistency in an independent population-based Swedish dataset. 
  
In paper III, through a series of experiments and association analyses, we could demonstrate 
a potential mechanism underlying the often perceived link between carbohydrate 
consumption and IBS symptoms. Rare sucrase-isomaltase (SI) mutations were more common 
in IBS patients compared to controls or the general population, and we also provide evidence 
of a functionally relevant coding SNP that significantly increases the risk of IBS, especially 
diarrhea-predominant IBS. This study suggests that milder forms of genetically derived SI 
deficiency may be present in subgroups of patients currently classified as IBS. 
Finally, paper IV represents an important step in an alternative strategy for the identification 
of IBS risk genes and variants; a general population-based approach utilizing existing data in 
large epidemiological cohorts and biobanks. Here we conducted a meta-analysis of a total of 
1,335 IBS cases and 9,768 asymptomatic controls from five independent European GWA 
studies, and although no genome-wide significant association was detected, the results from 
this study identify seven suggestive IBS risk loci for further investigation and highlight ion 
channel activity as potentially implicated in IBS pathophysiology.  
In conclusion, elucidating the genetic architecture of IBS is a truly challenging task, but as we 
are making progress, the studies in this thesis represent a significant step forward. We 
provide evidence for the importance of specific genes (NPSR1, TRPM8 and SI) in the 
development of IBS and associated phenotypes in subsets of patients, contribute to the 
emerging evidence suggesting a role of ion channels in IBS pathophysiology, and confirm the 
applicability of using large general-population based cohorts for the discovery of IBS risk 
genes and variants. 
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1 BACKGROUND 
1.1 IRRITABLE BOWEL SYNDROME: THE CLINICAL ENTITY 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder and the most common 
cause of gut illness. IBS is not a dangerous condition per se, that is to say, it is not a life-
threatening disease. Nevertheless, it is definitively a serious matter. It is extremely common, 
has a high economic burden, and reduces peoples’ quality of life and working ability. At the 
same time, the etiology is poorly understood and established diagnostic biomarkers are 
absent; hence there is no specific cure. Therefore, there is an urgent need for improved 
understanding of this gastrointestinal disorder, and while the interest in IBS research has 
grown considerably lately, increasing hope has been put in genetic studies.1-6 By elucidating 
the genetic background of IBS we will gain important knowledge of its etiology, contribute to 
re-classification of this condition into subgroups based on underlying pathophysiology rather 
than symptoms, and identify pathways and biological targets that can be exploited for 
therapeutic purposes. 
1.1.1 Clinical appearance 
While the term organic disease describes a condition explained by structural or biochemical 
abnormalities of tissues, organs or systems of the body, instead, a functional condition relates 
to the presentation of symptoms without detectable organic explanations. In gastroenterology, 
a large portion of diagnoses is in fact functional. The first three leading symptoms prompting 
a visit to outpatient clinics in the U.S. in 2009 were abdominal pain (15.9 million visits), 
diarrhea (4.2 million) or constipation (3.2 million),7 and between 35% and 45% of patients 
seen in gastroenterology clinics will ultimately be diagnosed with functional gastrointestinal 
disorders (FGIDs).8, 9 With symptoms arising from different parts of the gastrointestinal (GI) 
tract, FGIDs constitute a group of GI disorders classified based on patients’ symptomatology 
according to diagnostic criteria developed by the Rome Foundation,10 and in “the absence of 
obvious anatomic or physiologic abnormalities identified by routine diagnostic examinations, 
as deemed clinically appropriate”.11 Based on this classification system, FGIDs in adults are 
divided into six subgroups depending on the location of the main symptoms. Irritable bowel 
syndrome (IBS) (Figure 1) belongs to the functional bowel disorders (FBD) —one of these 
six FGID groups. IBS is by far the most common reason for seeing a gastroenterologist, and 
also constitutes 12% of patients seeking medical attention in primary care practices.12 
The clinical presentation of IBS is characterized by recurrent abdominal pain or discomfort 
(“an uncomfortable sensation not described as pain”)13 in combination with alterations in 
bowel habits. Based on patients’ predominant stool pattern, IBS can be subtyped as diarrhea-
predominant (IBS-D), constipation-predominant (IBS-C) or mixed/alternating IBS (IBS-
M).11, 13 Patients who cannot be accurately categorized in one of these groups are assigned 
IBS-U (unclassified). The stool pattern is assessed using Bristol Stool Form Scale (BSFS; 
Figure 1C), which is a scale from 1 to 7 describing the stool consistency. The BSFS is a 
reliable surrogate marker for intestinal transit time (see further info in section 1.3); hence, 
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FIGURE	  1.	  Rome	  III	  criteria	  classification	  of	  IBS	  and	  its	  subtypes.	  Functional	  gastrointestinal	  disorders	  (FGIDs)	  are	  classified	  into	  six	  groups	  based	  on	  predominant	  symptom	  location.	  One	  of	  these	  is	  the	  functional	  bowel	  disorders	  (FBDs),	  which	  includes	  IBS.	  (A)	  Rome	  III	  diagnostic	  criteria	  for	  IBS.	  (B)	  Conceptual	  framework	  to	  illustrate	  the	  significant	  overlap	  that	  exists	  between	  the	  FBD	  conditions,	  which	  should	  be	  considered	  to	  be	  part	  of	  a	  spectrum	  rather	  than	  separate,	  isolated	  entities.	  Pain,	  diarrhea	  and	  constipation	  distinguish	  IBS,	  FC	  and	  FDr	  from	  each	  other,	  while	  bloating	  and	  distension	  are	  symptoms	  frequently	  reported	  by	  patients	  with	  any	  of	  the	  FBDs.	  (C)	  Subclassification	  of	  IBS	  using	  the	  Bristol	  stool	  form	  scale	  (BSFS),	  a	  reliable	  surrogate	  marker	  for	  intestinal	  transit	  time,	  to	  evaluate	  the	  consistency	  of	  patients’	  bowel	  movements	  (BMs).	  (B/C)	  Lacy	  et	  al.,11	  ©	  see	  page	  71.	  
Bowel	disorders	
	
Irritable	bowel	syndrome	(IBS)	
	-with	predominant	constipation	(IBS-C)	
	-with	predominant	diarrhea	(IBS-D)	
	-with	mixed	bowel	habits	(IBS-M)	
	-unclassified	(IBS-U)	
Functional	constipation	(FC)	
Functional	diarrhea	(FDr)	
Functional	abdominal	bloating/distension	
Unspecified	functional	bowel	disorder	
Bristol	
Stool	
Form	
Scale	
Rome	III	criteria*	
	
Recurrent	abdominal	pain	or	discomfort	≥3	days/month	in	the	
last	3	months	associated	with	2	or	more:	
Improvement	
with	defecation	
Onset	associated	
with	a	change	in	
frequency	of	
stool	
Onset	associated	
with	a	change	in	
form	(appearance)	
of	stool	
*	Criteria	fulfilled	for	the	last	3	months	with	symptom	onset	at	least	6	
months	prior	to	diagnosis.	
Constipation	
Diarrhea	
Pain	
A	
B	
C	
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this is a useful tool to evaluate abnormal bowel habits. Scores 1 and 2 indicate constipation 
pattern, 6 and 7 diarrhea, and 3-5 are considered normal types of stool. With ≥25% hard or 
lumpy stools (i.e., 1 or 2) and <25% loose or watery stools (6 or 7), patients are classified as 
IBS-C. Conversely, having ≥25% loose or watery stools and <25% hard or lumpy stools 
classifies as IBS-D. Patients with both ≥25% hard or lumpy stools and ≥25% loose or watery 
stools are placed in the IBS-M group. By capturing type, frequency and duration of 
symptoms, the Rome criteria were introduced in 1990 with the aim to separate healthy 
everyday GI symptoms from gut dysfunction,14 and have been updated three times since; 
1999-2000,15 2006,13 and the latest Rome IV as recently as 2016.11 Obviously, since Rome IV 
is very new, studies published to date, including those in this thesis, have used previous 
versions for phenotype definition (often III). Compared to Rome III (Figure 1A), the IV 
update contains a few revisions for IBS including the frequency of symptoms (on average ≥1 
day/week) and rephrasing of the criteria (the terms ‘discomfort’ and ‘onset’ removed, and 
‘Improvement with’ changed to ‘Related to’), overall making it a bit more restrictive. In 
addition, while subtyping according to Rome III is based on all bowel movements (including 
normal ones),13 the Rome IV criteria assess only days that contain symptomatic stools (i.e., 
loose/watery or hard/lumpy), attempting to reduce the unclassified subgroup.10 
Although not actually part of the Rome criteria for IBS, bloating is also commonly 
experienced and reported by more than 80% of patients,16 and is thus considered a supportive 
symptom that increases the confidence in the diagnosing of IBS.13 Overall, there is a 
significant overlap between IBS and other FBDs,17 and over time people tend to migrate 
between these, as well as between different IBS subtypes.18-21 Hence, while it may not always 
be possible to confidently separate these conditions as discrete entities, they should also be 
considered part of a spectrum (Figure 1B).11 In addition, other functional gastrointestinal 
disorders, such as reflux and dyspepsia, associate with IBS,17, 22 as well as several non-GI 
comorbidities, including pain syndromes (fibromyalgia, chronic pelvic pain, chronic fatigue 
syndrome, and migraine) and psychiatric conditions (depression, anxiety and somatization).23-
26 Moreover, a number of gastrointestinal diseases or conditions, e.g., celiac disease, 
inflammatory bowel disease (IBD), microscopic colitis or carbohydrate intolerance, can 
present with similar symptoms as in IBS and might therefore be misclassified as IBS if not 
detected in clinical examinations, or potentially delayed in their diagnosis.27, 28 The Rome 
Foundation encourages positive diagnosing of IBS, which means applying symptom-based 
criteria and performing limited diagnostic testing (such as colonoscopy, fecal calprotectin and 
blood tests) only in case of alarm signs (e.g., blood in the stool, unintentional weight loss, or 
family history of colorectal cancer or IBD).29, 30 However, in practice, IBS is more often 
considered a ‘diagnosis of exclusion’.31 
The most well documented risk factor for IBS is gender, as it manifests predominantly in 
women.32, 33 A comprehensive meta-analysis including 56 studies from around the world 
showed a significantly higher pooled prevalence of IBS in women (14.0%) compared to men 
(8.9%) with an international odds ratio of 1.67 (95% CI: 1.53-1.82),34 although significant 
heterogeneity between studies was observed. The incidence of IBS is not frequently reported, 
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but a U.K. study implemented in 123 general practices, utilizing medical registries, reported 
higher incidence in women (5.8 per 1,000) than in men (1.9 per 1,000).26 Stratifying by age, 
most patients were diagnosed in their early or middle life, with the highest incidence rate in 
the age span 25-44 years. Other studies suggest IBS risk to decrease after the age of 50, but 
due to significant heterogeneity between studies, the effect of age is unclear.35 
Irritable bowel syndrome has a significant and serious impact on sufferers’ well-being and 
quality of life.36 Only about one in four individuals meeting IBS criteria seek medical 
attention,37, 38 but those who do, utilize health care extensively.39, 40 Compared to undiagnosed 
individuals, those who consult a physician tend to report more severe symptoms, higher 
levels of anxiety and poorer quality of life.37, 41 In an international survey from 2009, 
including 1,966 IBS patients diagnosed by a physician, respondents reported their IBS to 
cause restriction of usual activities on average 73 days (20%) of the year, and almost 13% of 
patients were not working because of their health.40 In the same survey, patients would be 
willing to give up 25% of their remaining life (on average 15 years) and 14% would risk a 1 
in 1,000 chance of death in order to receive a treatment that would make them symptom free. 
This illustrates the real severity of IBS, and consequently, it has remarkably significant 
repercussions on health and socioeconomic systems.42, 43 The economic burden constitutes 
both direct (healthcare) and indirect costs. The latter involves societal costs related to 
education, social services and industry/work, including absenteeism (time off work) and 
presenteeism (reduced productivity whilst at work). However, estimating these is a truly 
challenging task, especially indirect costs, and together with the fact that a large number of 
undiagnosed IBS sufferers exist in the general population, and the unclear overall IBS 
prevalence, the total ‘price tag’ for IBS is not known. Reviewing previous attempts, 
variations in cost estimates are considerable. For example, direct cost (per IBS patient and 
year) may be between $742-$7,547 in the U.S. and £90-£316 in the U.K..43 Indirect costs 
attributed to IBS are even harder to calculate but constitutes approximately two-thirds of the 
total, and may correspond to about 0.5% of annual national healthcare budgets.42  
1.1.2 Worldwide prevalence 
The prevalence of IBS around the world is considerably large, usually reported on average 
between 10-20%.1, 38 In a meta-analysis from 2012 on compiled data from 260,960 
individuals and 80 separate study populations around the world, Lovell and Ford35 estimated 
a pooled prevalence of 11.2% (95% CI: 9.8-12.8%), see figure 2.1 However, the prevalence 
reported by individual studies varies substantially, ranging from 1.1% (U.S. and Iran) to 
45.0% (Pakistan) in this particular meta-analysis. Also in a more recent literature review 
published in 2017, IBS prevalence estimates span from 1.1% (studies from Iran and France) 
to 35.5% (Mexico),33 and due to large heterogeneity between studies, also within countries, 
the authors concluded a pooled estimate would not be appropriate nor meaningful. This large 
variation in reported estimates could partly be explained by non-consistent criteria for IBS 
definition and methodological variance. For example, in addition to using different 
classification criteria (i.e., Manning44 or Rome I/II/III13-15), the way of collecting data 
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(posted/electronic questionnaires, telephone interview or personal interviews) may also 
influence the response rates and results.33 The studies used in these literature reviews all used 
questionnaires or interviews and symptom-based criteria to capture IBS prevalence in the 
general population. However, if one would instead count the diagnoses present in the clinics 
(utilizing for example electronic medical registries, or simply asking patients if they have 
been medically diagnosed by their clinician) the numbers would look different, as you would 
only capture those who seek medical attention for their illness.37 Moreover, cross-cultural 
differences such as illness interpretation and reporting, attitude towards health care, dietary 
habits, environmental hygiene, microbiota composition variation, and genetic differences, are 
important aspects to consider when evaluating and comparing IBS between countries and 
cultures.45  
 
FIGURE 2. Worldwide prevalence of IBS. Data from population studies with results pooled by 
country and color-coded. Data from Lovell et al.,35 supplemented by additional studies from another 
nine countries. Figure by Enck et al.,1 © see page 71. 
1.2 IBS PATHOPHYSIOLOGY 
1.2.1 A disorder of gut-brain interaction 
“Trust your gut feelings.” “I’ve got butterflies in my belly.” 
We are all aware of the importance of our gut and its functions being closely linked to our 
mind and emotions, to the extent that it is even rooted in our everyday language. The 
relationship between our body and mind has been discussed for thousands of years and has 
had profound impact on the way science and medicine have developed.10  
In the past, since IBS is difficult to explain in the absence of structural (organic) findings, and 
at the same time shows a strong psychological component, a common view has been that the 
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term functional may indicate an idiopathic or cryptogenic condition, with patients often 
labeled as neurotic and to suffer from a perceived illness although being otherwise healthy.46 
However, the concept of IBS being functional is about to change as we are learning more and 
more about the underlying mechanisms.47 The development of more sophisticated methods 
now allows us to measure and detect ‘real’ abnormalities in IBS such as visceral 
hypersensitivity, inflammatory markers, gut microbiota composition, motility abnormalities 
and more, so it seems we are moving away from a purely symptom-based classification.48 
Although studies on IBS pathophysiology have been hampered by the lack of applicable 
biomarkers and the challenge in properly defining the IBS phenotype, the research interest in 
this area has remarkably expanded and there are now a number of factors and mechanisms 
proposed. We know today that psychological factors (e.g., stress, anxiety or depression) are 
indeed important in IBS,23 but rather than being causative they may be considered risk factors 
(together with social conditions and early life events) that can exacerbate gastrointestinal 
symptoms and determine the severity of illness and the clinical outcome.1, 10, 49 These 
psychosocial factors are part of a complex IBS pathophysiology model involving also 
environmental, genetic and physiological factors, such as mucosal immune activation, gut 
permeability, altered gut motility, visceral hypersensitivity, enteroendocrine and 
neuroimmune signaling, gut microbiota composition and activity, as well as food intolerance 
or carbohydrate malabsorption. This pathophysiology model can be described in different 
ways (as illustrated in several excellent reviews1, 29, 47, 50-52), and although the causality 
between involved factors is unclear, the overview picture tells us that IBS appears to be a 
condition with a brain-gut or gut-brain communication being somehow ‘out of tune’ (figure 
3, page 10). Hence, —and to also move away from the concept of them being functional—, a 
re-definition of FGIDs has recently been proposed by the Rome Foundation; Disorders of 
Gut-Brain Interaction.53  
Of note, IBS is not only a complex (multifactorial) disorder, but evidence also speaks for a 
highly heterogeneous phenotype in the sense that IBS should not be considered a single 
entity, but rather a mixture of various conditions all gathered under the same umbrella of 
similar symptoms. Furthermore, while the majority of IBS cases most likely have a 
multifactorial background with several contributing factors together causing disease onset, 
evidence also speaks for subsets of patients having specific underlying abnormalities, which 
on its own can induce IBS symptoms, such as in the case of bile acid malabsorption,54 
disaccharidase deficiencies,55 or specific ion channelopathies.56 Notably, this will also be 
reflected in their genetic predisposing background (see section 1.5 below). 
1.2.2 Risk factors in IBS 
As mentioned above, being female is the most obvious risk factor in IBS, as the condition is 
more prevalent in women than men in most countries worldwide.33, 34 Other FGIDs also 
manifest predominantly in women, although the reason for this is not clear.32 A role of sex 
hormones has been proposed, as they can modulate various processes that are related to IBS 
and the brain-gut axis, including pain processing, stress response, gut sensitivity and motility, 
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intestinal immune activation and barrier function. However, studies investigating the role of 
sex hormones in IBS are limited and difficult to conduct; hence, underlying mechanisms 
remain unknown.32, 57 Age (>50 years of age) may be associated with a lower risk of IBS, but 
the relation between IBS and age is unclear.35 Psychological factors and social environment 
(together referred to as psychosocial factors) such as anxiety, acute or chronic stress, illness 
behavior, coping, low quality of life, family history of substance abuse or mental illness, 
parents beliefs/behaviors, culture, socioeconomic status, social learning, social support, and 
early stressful life events, are all considered to influence the risk of IBS onset or severity.1, 49 
Moreover, presenting with other types of FGIDs, somatic pain syndromes (such as 
fibromyalgia, migraine or other), or psychiatric conditions, —which are all well-known 
comorbidities—, may also indicate higher risk of IBS, although it is unclear why these 
conditions co-exist.1 
Infectious gastroenteritis (of bacterial, viral or other origin) is a risk factor for IBS, in 
particular IBS-D and IBS-M.1 A systematic review and meta-analysis of eight studies showed 
a sevenfold increase in the odds of developing IBS after an infectious gastroenteritis (pooled 
OR 7.3 (95% CI, 4.7–11.1),58 and a more recent systematic review including 45 studies (total 
n=21,421), found that at 12 months after an infectious gastroenteritis episode, 10.1% had 
developed IBS (relative risk 4.2; 95% CI, 3.1–5.7) and at more than 12 months the 
prevalence of IBS had increased to 14.5%.59 Women are more likely than men to develop 
IBS after gastroenteritis, and other factors that seem to increase the risk include severity of 
the infection, psychological distress, depression, smoking and usage of antibiotics.59, 60 Other 
prospective studies have estimated that between 3–36% of GI infections lead to IBS,60 and a 
retrospective study reported that between 6–17% of IBS cases believe their IBS began with 
an acute gastroenteritis,61 and these patients are referred to as post-infectious IBS (PI-IBS). 
Finally, an underlying genetic predisposition exists in IBS, which can explain why some 
individuals are more susceptible to develop symptoms than others, and proposed risk genes 
play a role in several of the pathophysiological mechanisms presented below. However, the 
genetic background of IBS is the main focus of this thesis; hence it will be further discussed 
in detail in section 1.5.  
1.2.3 Pathophysiological factors 
Abnormal GI motility and visceral hypersensitivity (as defined by an increased sensation of 
stimuli from the gut) are important features of IBS, and early research on IBS 
pathophysiology in the mid–20th century was centered on these two specific entities.10 
However, assuming that these gut motor and sensory abnormalities arise due to specific 
underlying etiological factors, these features can also be seen as intermediate phenotypes (and 
potential endophenotypes) in between the IBS manifestation and its underlying 
pathophysiological mechanisms (see figure 3, and 1.3 below). The brain is responsible for 
receiving and processing incoming sensory information from the periphery, and has an 
important role in the modulation of pain response by either amplifying or suppressing the 
signal. This endogenous pain modulation includes noradrenergic, serotonergic, opioidergic, 
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dopaminergic and cannabinoid pathways, which facilitate or inhibit neuronal activity in the 
spinal dorsal horn.62 Pain perception is also highly influenced by mood (e.g., stress, 
depression or pleasure) and cognitive factors (e.g., expectations, memory and coping), and in 
addition, nociceptors (pain sensing nerve fibers) can be sensitized peripherally by for 
example injury or inflammation.62 There is evidence now demonstrating impaired central 
pain processing in IBS, and even existence of structural differences in the central nervous 
system (CNS) in some patients.52, 62, 63 However, through the autonomic nervous system 
(ANS) and the hypothalamic-pituitary-adrenal (HPA) axis the brain can also have effects on 
the gut,64 and proposed ‘brain-to-gut’ pathways in IBS suggest anxiety and prolonged stress 
(together with environmental, psychosocial and genetic factors) to directly or indirectly 
influence gut motility and secretion, barrier function, microbiota composition as well as 
mucosal immune response, which together lead to altered gut function and hypersensitivity.1, 
29, 50, 52 However, this brain-gut communication is very much bidirectional,52 and evidence 
from epidemiological studies suggests that in about half of IBS sufferers, GI symptoms arise 
first and psychiatric/mood comorbidities develop later, indicating ‘gut-to-brain’ pathways.29, 
47 Overall, the causality of events leading to hypersensitivity and other features of IBS is not 
clear, but several contributing factors have been proposed (further described below), 
involving both ‘top-down’ and ‘bottom-up’ mechanisms (figure 3).1, 29, 47, 50, 52 
The intestinal barrier is the epithelial lining of the gut, which constitutes an enormous 
surface with direct contact with the luminal environment, and plays a crucial role in the host-
microbe talk as a link between gut microbiota and the mucosal immune cells and enteric 
nervous system.65, 66 This barrier is recognized as being of importance in several diseases, 
including IBD and celiac disease, but also IBS, and increased permeability (or ‘leaky gut’) 
has been described especially in IBS-D and PI-IBS.65-68 Evidence suggests that environmental 
factors such as GI infection, medications, food components and the gut microbiota, all can 
cause increased intestinal permeability. At the same time, a permeable gut may allow more 
passage of bacterial or dietary antigens from the lumen across the mucosa, which is likely to 
facilitate a mucosal immune response with increased infiltration of inflammatory cells and 
mediators. This may in turn have effects on the enteric nervous system and neuromuscular 
function (causing dysmotility and diarrhea) and the upstream signaling to CNS (affecting 
pain perception and hypersensitivity, psychological well-being and behavior).29, 50, 65, 66, 68  
Observations that support the role of immune activation in IBS include increased risk of IBS 
after gastroenteritis,59 and the observation of IBS-like symptoms in IBD patients in 
remission.69 Several studies have indicated increased numbers and activity of immune cells 
infiltrated in the mucosa of the GI tract of IBS patients, especially mast cells,70 —a key 
component of the innate immune system. Mast cells in the GI mucosa lie close to sensory 
nerves, and signal to these using pro-inflammatory mediators (histamine, serotonin, proteases 
and others), causing peristalsis and pain responses, and possibly also sensitization.70, 71 At the 
same time, efferent neurons can also activate mast cells through the release of neuropeptides 
and other transmitters. This is one example of neuroimmune signaling; a complex 
bidirectional interaction between enteric neurons, terminals from extrinsic (ANS) nerves, 
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immune cells of the gut, and their mediators, which may contribute to increased permeability, 
changes in gut motility, and increased visceral pain perception in a subset of IBS patients.1, 70 
Interestingly, supernatants from colonic mucosal biopsies of IBS patients, but not from 
healthy controls, can activate enteric sensory neurons,72 and this effect is stronger when 
supernatants from hypersensitive, rather than from normosensitive, patients are used.73  
Neurotransmitters and neuropeptides are important in the brain-gut axis and have been 
implicated in IBS and associated GI symptoms and functions, with much attention being paid 
to serotonin (5-hydroxytryptamine, 5-HT).1, 47, 51, 74 This monoamine is an important 
neurotransmitter involved in various processes including the regulation of mood, behavior 
and well-being, but also has significant effects on gut motility, secretion and visceral 
sensation, with more than 90% of serotonin being produced in the enterochromaffin cells in 
the GI tract.75 Genetic studies, the effects from drugs targeting serotonin pathways on IBS 
symptoms and intestinal transit time, and observations of abnormal levels and impairment of 
serotonin metabolism and/or reuptake in IBS-D and IBS-C, all support the hypothesis of a 
dysregulated serotonin signaling in IBS.74-76 Moreover, previous work from our group has 
provided evidence of the involvement of another neurotransmitter, neuropeptide S, and its 
receptor in gut motor and sensory functions77 (further described in 1.5.5 below), which led us 
to perform paper I included in this thesis.  
Ion channels are transmembrane proteins found in all types of cells where they coordinate 
the passage of ions in response to different stimuli. They often have cell-specific functions 
and in the GI tract ion channels play important roles in gut functions such as GI motility, 
secretion and visceral sensation.78, 79 Channelopathies, i.e., dysfunctions (typically genetically 
derived) in conducting ions, are well established phenomena contributing to disease in the 
fields of neurology and cardiology, but are now also being increasingly recognized as 
important in the pathophysiology of FGIDs, in particular IBS.74, 80 For instance, about 2% of 
IBS patients, mainly IBS-C, harbor loss-of-function mutations in a voltage-gated sodium 
channel (encoded by the SCN5A gene) important for smooth muscle cell contractility and the 
slow wave function initiated by interstitial cells of Cajal (ICC) in the gut.56 There is also a 
growing body of evidence supporting the role of transient receptor potential (TRP) channels 
in IBS, especially in visceral pain perception.81, 82 The TRPV1 channel, a thermo TRP, has 
been particularly recognized and is believed to contribute to hypersensitivity and pain in IBS, 
possibly through sensitization of sensory nerves by mast cell mediators.70, 83 In paper II in 
this thesis, we also provide evidence of the potential involvement of another TRP channel 
(TRPM8) in IBS. Furthermore, recent work from our group in collaboration with A 
Zhernakova (University of Groningen) suggests ion channel activity to be implicated in gut 
function, based on the results from a first GWAS of stool frequency.84 Of note, many of the 
currently available pharmacological treatments for IBS, e.g., prosecretory agents such as 
Lubiprostone and Linaclotide (see 1.4 below), exert their action through activation or 
inhibition of ion channels, and with the increasing body of evidence on the importance of ion 
channels in IBS pathophysiology, these represent reachable and promising targets for IBS 
therapy.78, 80  
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FIGURE 3. An overview of IBS pathophysiology. Several risk factors, triggers and other contributing 
or involved factors have been described in IBS, and while the etiology is not well understood, the 
overview picture tells us that this is a multifactorial condition with a brain-gut or gut-brain 
communication that is somehow ‘out of tune’ —a disorder of gut-brain interaction. Notably, the IBS 
phenotype is heterogeneous and key pathophysiological factors may differ between patients. At the 
same time, subsets of patients may have specific underlying abnormalities responsible for their IBS 
symptoms. ANS, autonomic nervous system; CNS, central nervous system; ENS, enteric nervous 
system; GI, gastrointestinal; HPA, hypothalamic-pituitary-adrenal; ICC, interstitial cells of Cajal.  
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Gut microbiota is an extremely complex ecosystem residing in our GI tract, mostly in the 
colon, and consists of bacteria, archea, eukaryotes and viruses, although the bacteria domain 
by far outnumbers the rest. The rapid advancement in culture-independent molecular 
techniques (e.g., 16S rRNA sequencing) has enabled advancements in microbiota research 
and has shed light on its impact on various processes in the human body, with the 
microbiome now considered part of the gut-brain axis.50, 85 Available studies on an altered 
microbial community in IBS compared to healthy individuals provide good evidence to 
conclude that there is a difference, at least in a subset of patients.86, 87 Some studies suggest 
that while a subgroup of IBS tends to have a fecal microbial profile similar to healthy 
individuals, the other group shows a significantly different microbial pattern.88, 89 At the 
phylum level, higher relative abundance of Firmicutes and lower relative abundance of 
Bacteroidetes (the two most dominant phyla in the gut) seem to characterize this 
difference.87-90 However, there is heterogeneity and low reproducibility between studies, and 
it is not yet established exactly what types of microbial differences that exist and the causal 
effect in IBS is unproven.85-87 Moreover, the proposed role of small intestinal bacterial 
overgrowth (SIBO) in IBS pathogenesis is controversial and still remains under debate.86, 91 
The role of microbiota in IBS is very much unclear, but host-microbial interactions that may 
cause or influence IBS symptoms include activation of mucosal immune response, increase in 
intestinal epithelial permeability, activation of nociceptive sensory pathways and effects on 
the enteric nervous system.86, 87 Interestingly, Crouzet et al. demonstrated that 
hypersensitivity to colonic distension can be transferred from IBS patients through fecal 
microbiota to germ-free mice,92 and microbiota composition has also been linked to 
abdominal pain in a general population sample,93 supporting a role of microbiota in visceral 
hypersensitivity. Moreover, fermentation of undigested dietary components is an important 
function that plays a major role in IBS symptom generation in some individuals, and this will 
be further discussed below. Gut microbiota is believed to have a heritable component where 
host genetics influence the formation of its composition.94 Despite its complexity and high 
inter-individual variability, over time, the composition within one person is fairly stable.95 
However, various factors can influence the composition: dietary changes being the most 
obvious one.96 Notably, a complex interplay exists between food, microbiota and intestinal 
transit time, as demonstrated in, for example, studies of germ-free and humanized mice,97 and 
association studies showing correlation between fecal microbiota composition and surrogate 
measures (stool consistency and frequency) for intestinal transit time in population-based 
populations.98  
Food components. The vast majority of IBS sufferers believe certain foods (including cereal-
based, diary products, legumes, fatty foods, and certain fruits and vegetables) provoke or 
worsen their gastrointestinal symptoms, and postprandial (occurring after a meal) symptoms 
are common.99-101 Although classical food allergies (IgE-mediated) are not convincingly 
linked to IBS, many patients still report on perceived food intolerances,102, 103 and restrict 
their diet by avoiding foods perceived as problematic.99, 104 A gluten-free diet has increased in 
popularity, not only in the IBS community but also in the general population, and the newly 
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defined condition non-coeliac gluten sensitivity (NCGS), experienced as intolerance to wheat 
products, is widely debated, as it is not clear whether the culprit is actually gluten.105 Wheat 
contains also other compounds such as amylase-trypsin inhibitors, wheat-germ agglutinin, 
starch (main part of the endosperm), as well as dietary fiber.104 The interplay between 
ingested food, products of digestion and the gut microbiota, is important to bear in mind 
when discussing IBS and diet, especially regarding carbohydrate and fiber intake. In a normal 
state (figure 4), the digestion of carbohydrates is initiated by salivary and pancreatic α-
amylase, which hydrolyzes starch —the major carbohydrate component in our diet— into 
smaller glucose disaccharides (maltase, isomaltase) and oligosaccharides (e.g. maltotriose 
and branched α-limit dextrins). In the small intestine, the digestion of these starch products is 
finalized by α-glycosidases (brush-border enzymes), namely maltase-glucoamylase 
(MGAM), which hydrolyzes α-1,4-glycosidic bonds in maltose and maltotriose, and sucrase-
isomaltase (SI), which hydrolyzes α-1,4-glycosidic bonds similar to MGAM but also 
branching α-1,6-glycosidic bonds in isomaltose and α-limit dextrins.106 Sucrase is also 
responsible for the breakdown of sucrose, and lactase hydrolyzes lactose. The final products, 
monosaccharides, are readily absorbed by enterocytes into the blood stream. In the colon, gut 
microbiota ferment nutrients that escape absorption in the small intestine, such as fibers, 
resistant starch and other non-absorbed carbohydrates, producing short-chain fatty acids 
(SCFAs) and gases. Although normal and unproblematic for most people, some individuals 
will experience troublesome symptoms such as bloating, excessive gas, diarrhea and pain.104 
In this aspect, some of the major factors that may play a role in IBS and should be considered 
are 1) hypersensitivity to ‘normal’ luminal stimuli, 2) the amount of poorly and non-absorbed 
carbohydrates in the diet, and 3) the ability to digest and absorb generally digestible 
carbohydrates.  
The ingestion of food will always set off a cascade of responses throughout the GI tract.107, 108 
Different stimuli, such as luminal distension, osmolarity, or food components will trigger 
autonomic nerve signals and hormone release, which stimulate enteric neurons, smooth 
muscle cells, or endocrine and secretory cells, resulting in gut motor and secretory responses, 
as well as the transmitting of sensory information up to the CNS. The working hypothesis in 
IBS is that, for some reason, hypersensitivity to ‘normal’ visceral stimuli exists,109 and it is 
therefore easy to assume that food must play a role, not necessarily as the underlying cause of 
IBS but at least as a trigger of symptoms in susceptible individuals prone to experience an 
exaggerated response to these stimuli.1, 87 A potential role of fat or other food components has 
been suggested, but limited evidence exists and most of the latest research has focused on the 
role of poorly absorbed carbohydrates in IBS symptom generation.104 
A generalized approach targeting several poorly or non-absorbed carbohydrates in the diet 
was developed in 2004 by Prof. Gibson et al. at the Monash University in Australia; the 
lowFODMAP (Fermentable Oligo-, Di- and Monosaccharides And Polyols) diet.110 This diet 
is well recognized across the world and is already implemented in clinical practice. The 
evidence for its efficiency has increased lately, based mainly on randomized trials, and 
overall 50–80% of patients seem to benefit.111 A randomized controlled trial (RCT) by 
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Halmos et al. observed a significantly lower overall GI symptom score in IBS patients on a 
lowFODMAP diet compared to a typical Australian diet, whereas no difference was seen in 
healthy controls.112 Other RCTs have reported overall improvement (adequate relief) of IBS 
symptoms in more than half of patients going on a lowFODMAP diet, but notably, compared 
with a diet based upon modified National Institute for Health and Care Excellence (NICE) 
guidelines (instructions to eat small frequent meals, avoid trigger foods, avoid excess alcohol 
and caffeine),113 or traditional dietary advice for IBS patients (limit the intake of insoluble 
fibers, fat, caffeine, gas-producing foods [i.e., legumes, onions, cabbage] and focus on regular 
and not too large-sized meals),114 the effects were somewhat similar. Both types of 
 
FIGURE 4. Human digestion of dietary carbohydrates in a normal state. Starch (the main 
carbohydrate component in our diet) is initially hydrolyzed by α-amylase from the salivary glands and 
pancreas, and finally broken down into glucose in the small intestinal brush border by maltase-
glucoamylase and sucrase-isomaltase. Isomaltase is also able to hydrolyze the branching points of 
starch products, such as isomaltose and α-limit dextrins. Sucrose is hydrolyzed by sucrase, and lactose 
by lactase. The final products, monosaccharides, are readily absorbed through enterocytes into the 
blood stream. α-A, α-amylase; M, maltase; G, glucoamylase; I, isomaltase; S, sucrase; L, lactase. 
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intervention diets improved overall IBS symptoms, although the study that compared the 
lowFODMAP diet with a modified NICE diet could observe significantly greater benefits in 
abdominal pain and bloating scores in patients one the lowFODMAP diet.113 The 
lowFODMAP diet is a ‘top-down’ approach, i.e., a strict elimination phase of a few weeks 
supervised by a dietician, is followed by a structured re-introduction of foods. This is 
important because of the potentially negative long-term effects on microbiota composition, 
quality of life, and the risk of inadequate nutrient intake.115 
Poorly digested or malabsorbed carbohydrates (whether FODMAPs or other) accumulate in 
the intestinal lumen where they will increase osmolarity (which drives water retention) and 
undergo rapid fermentation by colonic bacteria (producing SCFAs and gases). This causes 
distension and bloating, activation of sensory neurons, and acceleration of transit time.116 
This is also the main mechanism in enzyme deficiencies, such as lactose intolerance, where 
undigested lactose accumulates in the gut and gives rise to symptoms such as diarrhea, 
abdominal pain and bloating.117 In a survey from 2007, more than 50% of 1,242 interviewed 
IBS patients chose “Lack of digestive enzymes”, among other pre-formulated answers, when 
asked to guess what causes IBS, and the responders were also most interested in knowing 
“What foods I should avoid”.118 Of note, treatment with pancrealipase, a combination of three 
digestive enzymes, has shown symptom improvement in postprandial IBS-D patients.119 
Moreover, in a study from 2012, low activity of one or more disaccharidases was detected in 
50% of 44 children with dyspeptic symptoms,120  and similar findings were reported in a 
recent study from 2017, where low disaccharidase activity was detected in 50% of 203 
pediatric patients with normal histology who had undergone endoscopy with chronic 
abdominal pain as the primary indication.121 In the clinical evaluation of suspected IBS 
patients, lactose and sometimes fructose intolerance (examined by hydrogen breath test or a 
trial period of elimination from the diet) may be considered.1, 30 However, more rare enzyme 
deficiencies tend to be overlooked and may be misdiagnosed as IBS, in particular 
postprandial IBS-D.101 Sucrase-isomaltase (SI) deficiency is an example of such a condition, 
and in paper III, through a series of experiments and association analyses of SI genetic 
variation, we provide evidence of a role of SI deficiency in IBS. 
Moreover, Bile acids (BAs) are important for human digestion as they act as lipid detergents, 
enabling degradation and absorption of fat in the small intestine. The BAs are synthesized in 
the liver and secreted into the lumen of the duodenum, and after aiding in fat absorption, 95% 
are actively reabsorbed in the terminal ileum and recycled through the ‘enterohepatic 
circulation of BAs’.122 In the case of bile acid malabsorption (BAM), excess concentration of 
BAs in the colon may cause secretion of water and electrolytes, accelerate colonic transit and 
motility, alter mucosal permeability and increase visceral sensation, which together result in 
diarrhea and symptoms typical for chronic diarrhea or IBS-D.51, 122 In fact, on average around 
30% of patients with severe diarrhea-predominant IBS have evidence of BAM, as 
summarized in systematic reviews.54, 123 Several plausible mechanisms of BAM have been 
proposed, with strongest evidence for a dysfunction in the negative feedback regulation of 
BA synthesis, a mechanism mediated by the endocrine fibroblast growth factor 19 
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(FGF19).122, 124 Hence, bile acid malabsoption may be mainly responsible for symptoms in a 
particular subset of IBS-D. 
1.3 ENDOPHENOTYPES OF IBS 
As described above, IBS is usually sub-grouped based on predominant GI symptoms. 
However, over time, patients often move between IBS subgroups or even similar FBDs 
(figure 1B, page 2), indicating a spectrum of disease and not distinct entities.11, 17-20 
Considering this, the Rome criteria and symptom-based subgrouping may represent valuable 
instruments in the clinical management of IBS patients to help direct treatments (which often 
focus on symptom amelioration), but may be less informative in research and poorly 
applicable to predict the molecular mechanisms that contribute to IBS. Therefore, another 
alternative strategy for IBS gene discovery is to, in addition to the classical clinical 
phenotype, also use endophenotypes.4 This concept can be traced back to 1966125 and was 
introduced in the psychiatric field by Gottesman and Shields in 1973126 as a way of 
deconstructing psychiatric illnesses into simpler components and to bridge the gap between 
symptom presentation and genetic variability.127 Endophenotypes are measurable, often 
quantitative, intermediate traits, associated with both the disease and the underlying genetics, 
and have been widely used successfully not only in the psychiatric field but also for a variety 
of other complex traits, all of which include a genetic component and also constitute a group 
of conditions presenting with similar symptoms but with a potential mix of different 
underlying etiologies. Since endophenotypes typically are quantitative traits, an advantage 
from a statistical perspective to use them is also that they generally have better power to 
detect a genetic effect compared to binary traits.128 Examples of endophenotype-disease 
relationships are blood pressure and cardiovascular disease, and bone mineral density and 
osteoporosis. By definition, the difference between endophenotype and similar terms, such as 
intermediate phenotype, biological marker or subclinical trait, is the genetic connection.127  
In IBS, the most commonly used intermediate phenotypes (and potential endophenotypes) 
include measures of intestinal transit time and motility, visceral hypersensitivity and pain 
perception.4, 129 Altered gut motility and visceral hypersensitivity have been known to be key 
elements in IBS for a long time.10 The purpose of GI motility is to handle gut content, i.e., 
mix, store, and importantly, accomplish propulsion of gut content along the ~7 m long GI 
tract by peristalsis.108 Intestinal dysmotility is common in IBS, and in those with abnormal 
transit time, slower transit time associates with constipation whereas faster transit time often 
indicates diarrhea,130 hence intestinal transit time is considered a solid and objective trait for 
the evaluation of GI dysfunction. However, available methods and techniques to measure 
transit time require specific equipment and may be expensive and sometimes invasive, hence, 
and especially for the purpose of larger population-based studies, surrogate markers may be 
used instead. Stool consistency, assessed by using a Bristol stool form scale (BSFS), has 
shown to correlate well with transit time,131, 132 and the BSFS tool is also used to characterize 
IBS patients according to the Rome criteria.11 In addition, stool frequency (recorded through 
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bowel habit diaries) has also shown correlation and can therefore be considered another 
reliable surrogate marker for transit time.130, 133 
Visceral hypersensitivity is central in IBS, and some studies have reported GI symptom 
severity to associate with visceral sensitivity.134 Other studies have shown that about half of 
IBS patients are hypersensitive to visceral stimuli while the other half can be considered 
normosensitive,83, 135 although the definite number is uncertain (various studies have 
described visceral hypersensitivity in 20–90% of patients).109 Visceral hypersensitivity can be 
assessed using for example rectal barostat studies with recordings of rectal compliance 
(capacity of the gut to adapt to intraluminal distension),108 and subjective measurements of 
the perception of visceral stimuli (i.e., pain and sensation thresholds and ratings).77 Moreover, 
other potentially useful intermediate phenotypes, and proposed endophenotypes, in IBS 
include inflammatory markers (mucosal immune cells or inflammatory mediators), bile acid 
kinetics, intestinal permeability, or even gut microbiota composition (e.g., 
Firmicutes/Bacteroidetes ratio).4, 129 Interestingly, recent studies have also explored the use of 
different brain imaging techniques to measure brain response to visceral stimuli in IBS, and 
in an interesting review of a systems view of IBS, Mayer et al. suggest that different brain 
signatures, or ‘intermediate brain phenotypes’, interact with intermediate gut phenotypes to 
together shape the clinical presentation of IBS.52 
1.4 MANAGEMENT AND THERAPEUTIC OPTIONS 
Because of its complexity, heterogeneity and largely unknown etiology, IBS is difficult to 
treat. There is no cure, and by using a trial-and-error approach, therapeutic management can 
only be based on patients’ individual symptomatology with available treatment options 
directed towards symptom amelioration. Predominant symptoms, the level of severity, and 
patients’ and practitioners’ preferences, usually is what determines the choice of treatment.30 
Much of the pharmacological agents used in IBS focus on normalizing bowel habits, while 
visceral sensation and pain seem to be more difficult to treat.136 Available pharmacotherapies 
include intestinal prosecretory agents (acting on ion channels or receptors on enterocytes, 
causing increased secretion of electrolytes and water into the lumen), antispasmodic drugs 
(agents that block muscarinic receptors or calcium channels on GI smooth muscle cells, 
causing relaxation and relief of pain), antidepressants (central sensory modulators, e.g., 
selective serotonin re-uptake inhibitors (SSRIs)), serotonin receptor antagonists/agonists 
(regulating gut motility and transit time), and others.136, 137 However, most of these drugs 
have only low or moderate quality of evidence and their level of recommendation is often 
low.136, 137 It is important though, to remember that IBS is a heterogeneous condition, and as 
long as IBS patients are all clustered together and sub-grouped solely based on symptoms, 
one cannot expect all IBS patients in a clinical trial to benefit from a specific treatment, and 
systematic reviews of their overall efficiency may be difficult to interpret. In the end, therapy 
strategies will be highly individual and, as long as a specific targetable cause is not identified 
in a patient, a combination of different types of treatments may be necessary, including also 
for instance dietary interventions, probiotics and psychological therapies.30  
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 “Let food be thy medicine and medicine be thy food.” Hippocrates 
The first-line dietary treatment for normalizing bowel habits is to adjust the intake of fiber.29 
However, this is not as easy as it may sound, as a wide variety of dietary fibers exist and their 
properties (soluble/insoluble, viscous (gel-forming)/non-viscous, short-/long-chain, and their 
level of fermentation by gut bacteria) will determine the effects on IBS symptoms.138 
Supplementation of psyllium, a long-chain, soluble and moderately fermentable dietary fiber, 
has been especially recognized as beneficial for IBS global symptoms, with solid evidence 
for its efficiency,137 whereas insoluble fiber (e.g., bran) does not seem to be of particular 
benefit in IBS.137-140 However, available studies typically include all IBS in the same 
treatment group, hence data on subtype specific effects are lacking. Of note, increased fiber 
intake can also induce uncomfortable adverse effects such as abdominal pain, diarrhea or 
constipation, and bloating, and for this reason, their use in IBS is controversial.138 Another 
dietary strategy, especially for diarrhea and bloating symptoms, is to try minimizing the 
production of gas by avoiding highly fermentable carbohydrates. This is the concept of the 
lowFODMAP diet (described in section 1.2.3 above), which limits the intake of a number of 
poorly absorbed short-chain carbohydrates due to their gas producing (through microbial 
fermentation) but also osmotic (attracts water) effects that can induce symptoms in some 
people.111 The proportion of patients reporting symptom relief on a lowFODMAP diet is high 
(50–80%),111 and can be compared with the clinical effect of certain drugs commonly used in 
IBS, such as Lubiprostone (a prosecretory agent, which activates ion channels in the intestinal 
lumen and is used for the treatment of IBS-C and chronic constipation) with 18% of patients 
reporting improvement in global symptoms.141 However, some FODMAPs (fructo- and 
galactooligosaccharides) also have prebiotic effects, hence a lowFODMAP diet may have 
negative impact on microbiota composition,142 and long-term effects are unknown.111 
Therefore, it is also notable, that when comparing the lowFODMAP diet with traditional 
dietary advice for IBS (NICE guidelines),143 which is less restrictive and focus more on how 
and when to eat rather than on what foods to avoid, no significant difference for overall IBS 
symptoms is observed between the diets,113, 114 —both dietary interventions are beneficial for 
about half of patients. This suggests that even though a strict diet can prove beneficial in IBS, 
it may not be necessary to introduce it to all patients. Instead, for some of them, smaller 
changes in dietary habits may be sufficient to improve their IBS symptoms, and dietary 
recommendation and guidance should be as individualized as possible.  
Gut microbiota is an important player in IBS, acting as a link between several involved 
factors, and while providing health benefits for the host it can also contribute to gut 
symptoms. Thanks to its ability to adapt (by altering composition and/or activity) in response 
to a change in the luminal environment, gut microbiota also represents a promising 
therapeutic target. It can be modified using diet, or more specifically, prebiotics (non-
absorbed fermentable carbohydrates, primarily oligosaccharides), but also with probiotics 
(live microorganisms with health benefits for the host), and even antibiotics. Available data 
has demonstrated that probiotics are effective in the therapy of IBS, not only in terms of 
improvement in overall IBS symptoms, but also specifically for abdominal pain, bloating and 
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flatulence (gas),144 although it is unclear what types of bacterial strains should be used. Due 
to lack of data and heterogeneity between studies, there is insufficient evidence to conclude a 
positive effect from prebiotic or synbiotics (pre- and probiotics combined) specifically for the 
treatment of IBS.144 Moreover, the antibiotic rifaxamin has shown efficiency for IBS-D in a 
few clinical trials, but the mechanisms are not clear and there are obviously concerns for 
long-term or repetitive use of antibiotics.137 
Not to forget, IBS is in most patients a complex condition, and for successful clinical 
management, one must look at the big picture of the condition and address also extra-
intestinal manifestations such as psychiatric comorbidities. There are a number of different 
therapies available that may be of benefit in the management of IBS, including cognitive 
behavioral therapy, hypnotherapy and other psychological therapies.1, 137 Importantly, in 
addition to stress management and keeping in general a healthy diet, other lifestyle factors 
may be of importance. For instance, increased physical activity has shown to improve GI 
symptoms in IBS.145 In summary, the clinical management of IBS may have to combine 
several lines of treatments, targeting the symptomatology from different angles 
simultaneously. At the same time, by gaining knowledge on the underlying pathophysiology 
and identifying useful biomarkers, we strive to improve the ability to better predict who is 
going to respond to what treatment. 
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1.5 GENETICS OF IBS 
1.5.1 Studying the genetics of complex diseases; what, when, why, how? 
What do we study? In terms of our DNA, humans are approximately 99.9% similar, which, 
importantly, also means we are 0.1% different (or more, depending on what types of genetic 
variation is considered). This difference can be anything from large structural changes of the 
DNA sequence to changes in single base pair positions, i.e., single nucleotide variations 
(SNV), which is by far the most abundant type of genetic variation.146 By definition, a 
common variant or single nucleotide polymorphism (SNP) is present in more than 1% of the 
population (minor allele frequency, MAF>0.01), whereas rare variants (often referred to as 
mutations) are less common than that. While most of these variants have negligible or 
unknown effects, some will for example cause an amino acid change in the corresponding 
protein (missense/coding variants) or may alter levels of transcription (expression 
quantitative trait loci; eQTL), which will have implications on biological systems in the 
body.128 
‘Genetic architecture’ is a fancy term used to describe the characteristics of the genetic or 
heritable component of a phenotype/trait. It encompasses the type and number of genetic 
variations that influence the phenotype, their population frequencies, magnitudes of effects, 
as well as interactions with each other and the environment.146 Rare genetic conditions, such 
as cystic fibrosis, are highly heritable and typically show a Mendelian inheritance pattern.128 
These conditions are caused by one or more rare variants in single genes, which have 
detrimental effects on the corresponding protein and strong influence (high penetrance) on 
the disease risk. However, most common diseases and traits, such as cardiovascular disease, 
diabetes or height, do not follow a classical Mendelian inheritance pattern even though they 
show heritability. These all have a complex genetic architecture with multiple genetic 
variants involved (i.e., polygenic). The ‘Common Disease, Common Variant (CDCV)’ 
hypothesis argues that the genetic component of common diseases is mainly composed of 
many variants that are also common in the population, all with relatively small effects (low 
penetrance) and risk ratios typically around 1.2–2.0.128, 147 Indeed, GWAS efforts over the last 
few years have successfully identified common genetic risk variants for a variety of common 
diseases and traits. The National Human Genome Research Institute GWAS catalog 
(http://www.ebi.ac.uk/gwas/)148 now lists over 58,000 unique SNP-trait associations from 
3,308 publications (last data release 2018-02-21), indicating that the CDCV hypothesis is 
probably true for most common diseases. However, identified SNPs for a trait together often 
explain just a fraction of the genetic component, whereas a large portion remains 
unexplained.128, 147 Take human height for example; in 2014, through large collaborative 
efforts and GWAS data from a total of 253,288 individuals, 697 genome-wide significant 
variants had been identified, though these variants together explain only 20% of the 
heritability for adult height.149 Obviously, other forms of genetic variation or epigenetic 
effects may contribute to the ‘missing heritability’, but the ‘Common Disease, Rare Variant 
(CDRV)’ hypothesis argues that also rare variants can be the major contributor to common 
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diseases, and, as discussed by Schork et al.,147 the truth probably lies somewhere in between. 
The genetic architecture can be a mix of both common and rare variants on a spectrum of 
different combinations for different traits,146, 147 and IBS is not an exception.4-6 A heritable 
component of IBS has been demonstrated (see next section 1.5.2), and for most IBS patients, 
a complex and polygenic background with many genetic variants (mostly common) is 
thought to together contribute to disease (figure 5). Furthermore, specific combinations of 
these genotypes (together with environmental factors) may explain in part the clinical 
heterogeneity of the IBS phenotype, i.e., there are likely different sets of genes that can 
explain different features of IBS (e.g., related to diarrhea/constipation, pain perception, 
immune response or susceptibility to psychological comorbidity).6 At the same time, 
evidence points to the existence of smaller IBS subgroups where rare high-penetrating single 
gene variants may principally account for their symptoms, as for example in the case of 
specific ion channelopathies (see 1.5.5 below).5, 56 
 
Figure 5. Hypothesis of the genetic background of IBS. 
When is the right time to study the genetics of a disease? Whenever a trait of interest, for 
example IBS, shows a pattern of inheritance, as assessed by family aggregation or twin 
studies, then genetic studies can prove to be meaningful. Since the Human Genome Project, 
which successfully completed the first sequencing of the entire human genome in 2003,150 
technical as well as methodological development has expanded extremely rapidly, and is now 
in a very advanced stage compared to just a decade ago.151 Especially the development of 
SNP arrays, containing broadly between 200,000 to several million SNPs on one chip 
(representing common variations across the entire genome), has enabled hypothesis-free 
studies on the genetic background of complex diseases through genome-wide association 
studies (GWAS). The considerable decreases in costs for these SNP arrays, together with 
sharing of genetic data (publicly available databases, and international collaborative efforts) 
in the gene-mapping community, are key factors that now enable large-scale analyses to be 
performed. In addition, the generation and mapping of functional annotation data, also in 
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specific disease-related tissues, provided by large projects such as ENCODE152 and GTEx,153 
as well as a variety of available tools for post-GWAS functional analyses are of great help 
when trying to make biological sense out of the genetic association findings. Hence, we 
currently are right in the middle of an exciting era of genetic studies.151  
Why? The ultimate goal of studying the genetics of a disease is to gain insight into the 
underlying biology, hoping that a better understanding of the disease will help in prevention, 
diagnosis, prognosis and improved therapy.128, 146, 151 Specific genetic testing can serve as a 
diagnostic tool for Mendelian single-gene diseases (e.g., cystic fibrosis), but may be poorly 
applicable on an individual level for the diagnosis of complex polygenic conditions. 
However, genetic information may be used on a population level to predict who is at risk of 
developing the disease, in order to stratify people and direct preventive interventions to those 
at higher risk. This may be of particular importance for life-threatening conditions such as 
cancers (offering earlier or more frequent screening programs) or conditions where 
preventive interventions or lifestyle recommendations may be of particular importance, e.g., 
cardiovascular disease or type 2 diabetes. In terms of IBS, genetic research represents a 
valuable tool that will, through the identification of risk genes and key biological pathways, 
provide important insight into the pathophysiology. In addition to improve understanding of 
what it is that we call IBS, a major goal is to be able to re-classify this condition into novel 
subtypes based on molecular patterns and an underlying biology rather than the clinical 
symptomatology.3, 5 This is in line with the precision medicine approach, aiming to better 
individualize treatment and management of patients by taking into account different layers of 
information and individual variability, including genomics.154 While precision medicine is 
becoming a reality in some areas (e.g., cancer), it is the aim for also other complex diseases 
and disorders, such as in the psychiatric field,155 as well as in IBS.3  
Even though SNPs may have small effects on disease risk, their corresponding proteins or 
pathways may still be suitable targets for therapies and drug development.146 One can argue 
that if small effects on protein level correspond to small effects on the disease, then if 
consistent, large effects on protein level may translate into large effects on the disease.146 In 
other words, SNPs can help to highlight targetable proteins. There are many examples of 
pharmaceuticals that have proven clinically beneficial even though associated SNPs near the 
drug target each have small effects.146 It is also possible that several associated SNPs or risk 
genes all act in the same pathway or process in the body. Hence, those findings may together 
point out a pathways relevant to the disease, which may be worth further investigation.  
Moreover, the area of pharmacogenetics is emerging, which aims to understand how genetic 
variation influences drug metabolism (pharmacokinetics) or drug activity and receptor 
binding (pharmacodynamics), to be able to better predict drug responsiveness and proper 
dosing for different patients, in line with the movement towards precision medicine. Despite 
the lack of established risk genes, several pharmacogenetic studies in FGIDs have already 
been conducted, investigating the effects from genes in the CYP450, serotonergic, 
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cannabinoid, adrenergic and bile acid pathways.156 This is an interesting area of research, 
although still in its infancy.   
How do we study the genetic architecture? For those who are not very familiar with genetic 
studies, here follows a short section on the basic principles and workflow for conducting such 
studies. Genetic studies test the relationship between genetic variation and a phenotype of 
interest, and while a well defined phenotype is the key in these studies, this is also the 
fundamental issue and challenge when it comes to IBS (see 1.5.4 below). Large international 
projects, such as the HapMap157 and 1000Genomes158 projects, have been crucial for enabling 
genetic studies in different populations, as these have sequenced a number of people from 
different populations and created publicly available catalogues of their genetic sequence. 
These serve as reference panels providing important information on 1) the location and 
density of genetic variants, 2) the relation between these (described as linkage disequilibrium 
[LD]; a measurement of co-inheritance based on recombination rates in a population) and 
their haplotype structures, and 3) differences between populations. These catalogues have 
been particularly useful for designing chip-based microarrays (for the purpose of GWAS), 
since one can pick suitable markers that act as proxies for related SNPs and thereby covering 
more of the variation across the genome without having to genotype redundant information. 
Closely associated SNPs (based on LD) can instead be imputed afterwards based on these 
tagging markers and linkage information in appropriate reference panels.128 A limitation of 
many of these SNP arrays is that they cover well the common polymorphisms (MAF>1%) 
but poorly capture rare variants, but as technology is developing and costs go down, we are 
moving into an era where high coverage sequencing chips that include also rare variants 
(exome and whole-genome sequencing) are more frequently used.151 
Once phenotype information has been collected, and genetic variation captured, each SNP 
can be tested independently for its association with the phenotype. In hypothesis-driven 
candidate-gene studies or replication studies for the validation of previous results, a few 
genotyped variants in a specific region may be tested. On the other hand, in a hypothesis-free 
GWAS approach, hundreds of thousands to millions of SNP-phenotype tests are 
simultaneously conducted across the entire genome. Obviously, with that many tests 
performed, there will be a need for multiple testing correction, and based on a simple 
Bonferroni correction, the gold standard in GWAS is currently a p-value threshold of  
5.0×10-8 (α of 0.05 /1,000,000).128, 159 To statistically test the association of a genotype with a 
binary trait (case/control), contingency table tests (Chi-square, Fisher’s exact or Cochran-
Armitage trend test) can be used or, if covariate adjustment is necessary, typically logistic 
regression. Moreover, there are a number of models that test different types of genetic effects 
(allelic, genotypic, dominant, recessive and other) but the additive genetic model, which 
assumes a linear increase in risk for each copy of the risk allele, is most commonly used as it 
has reasonable power to detect both dominant and additive effects.128, 159 Covariates should be 
considered, such as gender or study center, and in GWAS also the potential impact of 
population stratification. Moreover, before association testing can be performed in a GWAS, 
rigorous quality control (QC) is performed on the data to check the quality of samples 
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(including call rate, gender check, unexpected relatedness and population stratification) and 
markers (genotype call rate, MAF and Hardy-Weinberg equilibrium).160 Appropriate 
computational software’s to use include, among others, R, SNPTEST and PLINK (publicly 
available), or the commercially available SNP & Variation Suite (SVS). 
Importantly, results from genetic association studies should then be validated through 
replication in independent cohorts, and meta-analyses or pooled analyses may also be 
performed combining the results from several similar studies to evaluate if the same effect is 
seen throughout and to increase sample size and power to detect association.128, 159 Finally, 
the challenge of interpreting the results and linking them to biology remains, which is not 
always that straightforward.151 Various post-association analyses can be performed for fine-
mapping of results, to gain information about the genomic content and try to identify causal 
variants responsible for the association. In silico analyses (using available online tools and 
databases) can also help in predicting the effects from risk variants on gene products, 
correlating with expression levels in different tissues, or perform pathway analyses through 
for example gene-set enrichment analysis (GSEA). Moreover, other functional 
characterization analyses include in vitro experiments and studies of mRNA or protein levels 
in biological material from patients and healthy controls.  
1.5.2 Heritability of IBS 
A heritable component in IBS is present, and has been demonstrated in several ways.6 Some 
studies have evaluated the familial clustering of IBS by simply asking affected members if 
they have another family member affected by IBS (i.e., proxy reporting), but since the 
accuracy of this type of reporting is poor,6, 161 Saito et al. performed a larger family case-
control study in 2008.162 By collecting IBS symptom data (questionnaires) and medical 
history (electronic medical register) for 477 IBS cases, 297 controls and their (1,492 and 936, 
respectively) first-degree relatives, they found it to be 2–3 times more likely that a relative of 
a case had IBS (50% of cases had at least one affected relative) compared to controls (27% 
had at least one affected relative). Several twins studies on IBS have estimated the heritability 
—the percentage of phenotypic variance that is due to inherited genetic factors— to range 
between 0–57%,6 suggesting a genetic component despite the notable heterogeneity in 
heritability estimates. Moreover, in 2015, a comprehensive register-based Swedish national 
survey, including 51,952 individuals diagnosed with IBS, showed increased risk of IBS 
among first-, second- and third-degree relatives, clearly demonstrating the existence of a 
genetic component.163 Not surprisingly, a non-genetic (environmental) component was also 
suggested to contribute, as seen by the clustering among spouses in this study. In addition, the 
same authors recently contributed with a study on familial aggregation of IBS among 
adoptees, and could confirm once again a role of genetics as the risk of IBS in adoptees was 
higher if their biological parents, rather than their adoptive parents, were diagnosed with 
IBS.164 Heritability in this study was estimated to 19.5%±8.5%. Taken together, several lines 
of evidence suggest IBS has a substantial heritable component, but that genetic factors also 
interact with environmental factors to form this complex phenotype.  
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1.5.3 IBS genetics so far 
Genetic studies, and especially GWASs, have been successful in mapping the genetic 
background of a variety of complex diseases, including gastrointestinal conditions such as 
inflammatory bowel disease (IBD) where a total of 200 genetic risk loci have been 
identified.165, 166 However, IBS has been very much lagging behind. 
In 2013, at the time of the start of this PhD project, more than 60 genes had been investigated 
for their potential role in IBS and its clinical subtypes. These have already been extensively 
reviewed elsewhere,3, 6, 129, 167 but include genes involved in immune function, bile acid 
metabolism, intestinal barrier function, neurotransmitter signaling, nociception and others; i.e. 
covering most of the above mentioned mechanisms/pathways that seem to be of importance 
in IBS. These were all candidate-gene studies with a prior and plausible hypothesis of a 
putative role of a specific gene in IBS pathophysiology, for example its involvement in GI 
motor or sensory function, or the immune response to the intestinal milieu. It should be noted 
though, that all of these previous studies were conducted in relatively small sample sets with 
often conflicting results, and most of the time not successfully validated or replicated in 
independent cohorts; hence, overall we had very few convincing IBS risk genes.4, 5 However, 
one exception might be TNFSF15, a gene encoding the TNF-like ligand 1A (TL1A), which is 
expressed by immune cells and amplifies the inflammatory response in the gut mucosa 
(figure 6).4 The original study conducted in our lab and the Mayo Clinic,168 aimed to 
investigate 30 established Crohn’s disease risk loci for their potential association with IBS, 
and found the risk allele G of the TNFSF15 SNP rs426839 to be more common in IBS cases 
than in controls (p=2.2×10-5; OR 1.37), especially in IBS-C (p=8.7×10-7; OR 1.79). The 
effect was observed in both of the case-control studies used (Sweden and USA, total 
n=1,992), and has also been replicated in additional cohorts since then.169-171 In the original 
study, the risk allele was also associated with higher TNFSF15 mRNA levels in blood and 
rectal mucosa,168 which, taken together, supports the hypothesis of immune activation in IBS, 
at least in a subset.  
Also other immune related genes have been suggested to play a role in IBS, but reported 
results have been inconsistent and further studies are warranted.171 Moreover, because of the 
presence and function of serotonin in both the brain and the gut, a large portion of the study 
efforts in IBS genetics so far has been put on the serotonergic system.6, 172 In particular, 
genetic variation in the promoter region of the serotonin reuptake transporter (SLC6A4) has 
been associated with IBS-D and IBS-C, but also with IBS comorbidities (depression and 
anxiety).3 Other genetic studies have focused on serotonin receptors and have provided some 
evidence of their involvement in IBS-D, especially the serotonin type 3 receptor (5-HT3), 
which is an ion channel encoded by the HTR3 genes. These studies together support the 
notion of disrupted serotonergic signaling in IBS, but further investigations are needed to 
confirm this hypothesis. Another gene worth mentioning is CDC42 (cell division cycle 42). 
This encodes a GTPase protein involved in the control of epithelial barrier function and has 
been linked to IBS-C in two independent cohorts.170 Nevertheless, at the time of initiation of 
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this PhD project, with possibly the TNFSF15 gene being the only exception, there were 
basically no unequivocal risk genes identified for the clinical phenotype of IBS.  
 
Figure 6 Schematic illustration of the hypothetical mechanism underlying association of TNFSF15 
polymorphism with IBS. DR3, death receptor 3; IFNγ, interferon gamma; Il-17, interleukin 17; TL1A, 
TNF-like ligand 1A. D’Amato,4 © see page 71. 
Another attractive approach for elucidating the genetic background of IBS and other FGIDs 
is the endophenotype approach, which I introduced in section 1.3 above. By using related 
intermediate traits instead of the typical clinical phenotype, the concept of this approach is to 
try reducing the complexity of the phenotype (disease) studied, and instead increase chances 
of finding genes important for the underlying biological pathways that contribute to the 
pathophysiology. Two convincing examples of this genotype-intermediate phenotype 
association in IBS are the neuropeptide S receptor (NPSR1, see next section) and the Klothoβ 
(KLB) gene, both of which have been implicated in lower GI motility.77, 124 Klothoβ is a co-
receptor with the fibroblast growth factor receptor 4 (FGFR4) on hepatocytes, and the coding 
SNP rs17618244 has been significantly associated with colonic transit time at 24 h in IBS-D 
(p=0.0018).124 In the enterohepatic circulation of BAs, reabsorption in the ileum causes 
negative feedback on hepatic BA synthesis, and this is mediated by this FGFR4/ Klothoβ 
complex upon binding of the endocrine factor FGF19 at the cell surface of hepatocytes.122 
Using a protein stability assay in HEK293 cells, the KLB Arg728 variant that associated with 
increased colonic transit time also appeared to reduce protein stability, which can explain its 
functional significance.124 An instable Klothoβ protein may limit the ability to down-regulate 
BA synthesis, which in turn causes increased concentrations of BAs in the intestines, 
resulting in accelerated transit time and bile acid induced diarrhea.122 Hence, this is an 
example of a specific mechanism that may be responsible for symptoms in a subset of IBS-D 
patients.  
Moreover, keeping in mind that IBS often arises from the interaction between genes and 
environment, and that psychosocial factors, stress, early life events and exposure to pathogens 
influence IBS risk, it is plausible to also hypothesize a role for epigenetics.1, 3 A few studies 
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have reported altered expression profiles of microRNAs in IBS, in particular IBS-D, and 
among others, Zhou et al. could demonstrate a role of certain microRNAs in visceral 
hypersensitivity and suggested that decreased expression of miR-199 contributes to visceral 
pain through upregulation of the ion channel TRPV1.173 Some animal studies also suggest 
that epigenetic mechanisms (such as DNA methylation or histone modification) may be 
implicated in stress-related alteration of the HPA-axis. However, epigenetic and microRNA 
studies are few, and these areas of research, as well as the area of pharmacogenetics, still 
remain in their infancy.3, 156  
1.5.4 Challenges in studying the genetic architecture of IBS 
‘Gene-hunting’ in IBS is extremely challenging.3-6 First of all, a clearly definable and stable 
phenotype is the cornerstone of any genetic study, and already there we hit our first (and 
major) obstacle. A trait/disease becomes more challenging to study when there is 
considerable heterogeneity, and this relates both to the level of precision to which the trait can 
be measured or diagnosed, but also to the biology behind it.151  
Measuring IBS is difficult. Due to our limited knowledge on the etiology, there are no 
established biomarkers or diagnostic tests,2 and symptom-based criteria is the closest we have 
to a gold standard for diagnosis and sub-classification of IBS and other FGIDs, although, in 
clinical practice IBS is still often treated as a ‘diagnosis of exclusion’.31 In addition, although 
regular updates of the Rome criteria (revised three times since 1990) are necessary in order to 
adapt to the increased knowledge that gradually emerges in FGIDs, this also means the 
definition of IBS is not stable over time. Moreover, the biology behind IBS also appears to be 
heterogeneous, as IBS is believed to be a constellation of different disorders gathered under 
the same umbrella of similar symptoms. Of note, this will be reflected in the genetic 
background, where some genes may be specific for certain subgroups or intermediate 
phenotypes of IBS.4, 5 
To compensate for this heterogeneity, large sample sizes will be necessary in order to 
improve statistical power of detecting an association. However, the number of available case-
control sets with well-characterized IBS patients from the clinics is limited, and while these 
serve as ideal replication and validation cohorts, the sample size needed for the discovery of 
risk genes and variants is considerably larger, at least if GWA studies are to be carried out.4 
In addition, considering the heterogeneity of the IBS phenotype and genotype, when 
combining or comparing data from different cohorts there is a risk of introducing center-
specific recruitment bias.3, 4 Suppose, for example, that IBS would be either a ‘brain-to-gut’ 
(i.e., psychiatric or stress conditions arise first and then influence GI function) or ‘gut-to-
brain’ (i.e., gut immune activation, ion channel dysfunction, or other factors that originate in 
the gut, drive the symptoms), then different focus and expertise at recruitment centers or the 
specific aims of the original investigation, may result in differences in the recruited study 
cohorts. In other words, a set of IBS cases from one center may be mostly characterized by 
psychiatric comorbidities whereas cases from another center perhaps originally sought 
medical attention due to suspected IBD or celiac disease, and might therefore be more prone 
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to have an inflammatory background. Hence, presumably, these groups would not only differ 
in terms of their etiology, but also in the genetic background with different sets of ‘IBS risk 
genes’ influencing functions primarily in the brain or the gut.4  
Not to forget, collecting controls can also be a challenge. Ideally, controls should be recruited 
in the same way as cases, using the same investigative instruments for their classification.3, 4 
Considering the high prevalence of IBS in the general population (also those fulfilling Rome 
criteria although they haven’t been diagnosed in the clinic), possibly hidden cases can be 
present among controls if IBS is not checked for. Moreover, exclusion criteria such as IBD or 
celiac disease should obviously also apply for both cases and controls. Finally, if a Rome 
module of questions is used, then individuals that fulfill only part of the IBS criteria should 
be classified as neither cases nor controls.4  
1.5.5 Our approach and previous work 
Recognizing that IBS appears to be a highly heterogeneous phenotype spanning from 
complex polygenic conditions to more rare single gene forms (figure 5, page 20), different 
strategies are needed for the identification of its genetic component.4, 5 This implies 
hypotheses driven candidate-gene studies but also large-scale genome-wide efforts. It may 
also be useful to challenge the traditional clinical phenotype by using other definitions or 
intermediate phenotypes. Importantly, results coming from these studies should then be 
validated through replication in well-characterized IBS cases and controls from specialized 
clinics, using targeted genotyping. To investigate also rare variants/mutations in subgroups of 
patients, sequencing of specific genes in well-selected cases and controls is necessary, and 
eventually even next-generation sequencing efforts of the entire exome or genome (figure 7, 
page 30). 
An excellent example of the existence of rare, but highly penetrant, single gene variants in 
subgroups of IBS, is the work done on SCN5A. This gene encodes the α-subunit of a voltage-
gated sodium channel (NaV1.5) responsible for the pacemaker function of the heart, and 
mutations in this gene are known to cause channel dysfunction (channelopathies) leading to 
cardiac arrhythmias, including Long QT and Brugada syndrome.174 However, NaV1.5 is also 
present on intestinal smooth muscle cells and the ‘pacemaker’ cells of the gut; the interstitial 
cells of Cajal (ICC),175-177 which creates slow waves that serve as an underlying rhythm for 
gut motility. The interesting observation that cardiac arrhythmia patients with SCN5A 
mutations often present with IBS-like gut symptoms,178 led to the hypothesis of a potential 
role of NaV1.5 channelopathies in IBS. Following a pilot study, where a rare SCN5A mutation 
was found in one of 49 IBS patients,179 the hypothesis was further investigated at the Mayo 
Clinic in collaboration with our group, where the SCN5A gene was sequenced in 584 IBS 
patients and 1,380 asymptomatic controls.56 Indeed, missense mutations were found in 13 
(2.2%) of patients but none of the controls. Most of these mutations had loss-of-function 
effects, and carriers most often had IBS-C. Of note, a severely constipated patient with the 
most highly penetrating SCN5A mutation identified could be successfully treated with a drug 
(mexiletine) known to rescue NaV1.5 defects. In addition, an association signal of common 
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variants was detected for the SCN5A gene in our pilot GWAS of IBS (described below)180 
and by genotyping 17 SNPs from this locus in four additional independent case-control 
cohorts (total n=1,745), this association could be confirmed.56 Hence, these findings not only 
support the notion of certain IBS subgroups having rare single gene conditions, but also that 
common variants may play a role (for instance through transcriptional control of the gene). 
Since ion channels are directly involved in both gut motility and visceral sensation, these 
represents ideal pathophysiological candidates and therapeutic targets in IBS.80 Therefore, in 
a follow-up study (paper II in this thesis), we aimed to investigate the role of also other ion 
channel genes in IBS. 
The traditional subgrouping of IBS, based solely on the presence of diarrhea and/or 
constipation (Rome criteria), can be a valuable instrument in the clinical management of 
patients as a help in choosing a treatment approach, but may not perform as well in predicting 
molecular mechanisms in research, or to identify specific genes that influence these 
mechanisms.4 For that reason, an alternative strategy for IBS gene hunting is to also use 
intermediate phenotypes (as potential endophenotypes), such as colonic transit time or 
visceral sensation (e.g., pain thresholds or scores in response to visceral stimuli); a concept 
introduced in section 1.3 above (and mentioned in 1.5.3). In line with this approach, our 
group has previously investigated the role of neuropeptide S (NPS) and its receptor NPSR1 in 
IBS-related intermediate phenotypes in a study of 699 cases with FGIDs and 233 healthy 
controls.77 While no significant association could be seen for the seventeen genotyped NPSR1 
SNPs by comparing symptom-based phenotypes (IBS/IBS-D/IBS-C/dyspepsia etc or total 
FGIDs) with healthy controls, instead, association was shown between some of the NPSR1 
polymorphisms and colonic transit time as well as sensory rating (gas, urgency and pain) in 
response to barostat-induced visceral distention. As part of the brain-gut communication, 
NPS-NPSR1 signaling is implicated in the modulation of anxiety, stress, fear, inflammation 
and nociception,181-186 and polymorphisms in the NPSR1 gene have previously shown 
association with anxiety and depression,183, 184 atopy and asthma,187-190 as well as chronic 
inflammatory diseases such as IBD191 and rheumatoid arthritis.192 The NPSR1 receptor is 
expressed in the brain but also in enteroendocrine cells in the gut,186 and previous work from 
our group have also demonstrated that NPS-NPSR1 signaling can induce the expression of 
other neuropeptides and gut hormones, including neurotensin, cholecystokinin, vasoactive 
intestinal peptide and somatostatin.77, 186 Based on these findings, and the proposed role of 
this receptor in nociception, it was then hypothesized that NPSR1 may be involved in visceral 
sensation and pain, which led to paper I in this thesis, where NPSR1 polymorphisms were 
tested for their association with recurrent abdominal pain (RAP) in children from a large 
Swedish birth cohort. 
Another recent example of the use of intermediate phenotypes in IBS genetic research, is a 
study coming from our group in collaboration with A Zhernakova (University of Groningen); 
the first GWAS of stool frequency.84 This study was conducted in two population-based 
cohorts from Sweden (Population-based Colonoscopy study; PopCol, n=284) and the 
Netherlands (LifeLines-DEEP, n=1,546).84 Although no genome-wide association signal was 
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detected, plausible candidate genes were identified, including genes involved in the 
cytochrome P450 pathway of drug and xenobiotic metabolism. Intriguingly, a broader post-
GWAS gene-set enrichment analysis of the genes located at the 53 loci showing suggestive 
association (p <5×10-5) with stool frequency indicated enrichment of those genes in pathways 
related to ion channel activity. In another study with the same lead author (F Hadizadeh, 
recently graduated PhD from our group), stool frequency was shown to associate with gut 
microbiota composition in 69 individuals from the Swedish PopCol cohort.98  
PopCol is a general population-based cohort of Swedish randomly selected individuals, of 
whom 745 volunteered to undergo an ileocolonoscopy, and a subset of these also kept 
detailed diaries of their bowel habits and symptoms for 7 and 14 days. In addition, blood and 
stool samples were collected.193, 194 Hence, PopCol represents a data-rich resource that has 
been particularly useful to explore the results from our candidate-gene studies in a general-
population sample, by for example correlating genotype with intermediate phenotypes, such 
as stool frequency or BSFS scores, or even abundance of fecal microbiota genera. In this 
thesis, data from PopCol has been exploited in both paper II and III. As mentioned above, 
the aim of paper II was to investigate the role of ion channel genes in IBS. Paper III is a 
nutrigenetic type of study where we through several steps tested sucrase-isomaltase (SI) 
genetic variants for their potential relevance in IBS, hypothesizing that SI deficiency (causing 
maldigestion and -absorption of sucrose and starch), although partial or in milder forms, is 
present in a subset of IBS patients. 
As described in 1.5.3 above, a number of studies have previously been performed in IBS, 
trying to investigate the role of specific candidate genes based on plausible hypotheses of 
their involvement in IBS pathophysiology. However, most of these studies suffer from 
limitations (mainly small sample sets and lack of replication data), —perhaps with TNFSF15, 
described above, as the only exception—, and it became clear that in order to eventually 
identify true unequivocal IBS risk genes and variants, especially common variation, large-
scaled analyses need to be implemented.4 Hypothesis-free GWA studies, investigating the 
entire genome, have been successful in a plethora of other complex diseases,151 but before the 
initiation of this PhD project, similar efforts had not been performed in IBS. In order to 
overcome some of the major challenges in IBS genetic research (including a heterogeneous 
phenotype and lack of suitably sized clinical cohorts) we proposed a few years ago, that a 
powerful approach might come from shifting to general-population samples (figure 7).4, 5  
Large biobanks and epidemiological cohorts from the general population, although originally 
often designed to answer other research questions, offer great opportunities to study also IBS 
because of its high prevalence in the general population. Large amount of data has already 
been collected in these cohorts, and despite an obvious loss in specificity, utilization of these 
resources will provide a considerable gain in sample size. Only the ‘tip of the iceberg’ of IBS 
sufferers is found in the clinics; most of them are undiagnosed, although fulfilling the IBS 
Rome criteria.37, 38 Hence, by using for example Rome criteria in questionnaires, we should 
be able to capture more of the IBS sufferers present in the general population. Depending on 
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what data is available, genotype data may also be linked to International Classification of 
Diseases (ICD) codes in electronic medical records (EMR), or even self-reported IBS 
(participants answering yes/no to “Have you ever been diagnosed with…?”). Reported 
diarrhea, constipation, abdominal pain, or intermediate phenotypes such as bowel movement 
frequency or Bristol stool form scale may also be exploited as alternative traits, depending on 
data available. Moreover, another advantage with working with general-population cohorts is 
that controls may be more appropriately defined, as they are co-sampled with the cases, and 
the very same investigative tools can be used to characterize both groups. For instance, 
considering the high prevalence of IBS symptoms, 10–20% of any general population sample 
may in fact constitute ‘hidden’ cases; hence, excluding individuals with reported GI 
symptoms from the control group should be helpful in avoiding these ‘false controls’.  
 
Figure 7. The proposed general population-based approach for the discovery of IBS risk genes and 
variants. Large general population-based samples may be exploited for IBS risk gene discovery 
efforts, and results coming from these studies then validated in well-characterized clinical IBS cases 
and controls. GI, gastrointestinal; GWAS, genome-wide association study. 
Shortly after my registration as PhD student, our group published a first GWAS of IBS, 
which marked the takeoff of our general population approach.180 In that study, a questionnaire 
module compatible with the Rome II criteria was used to identify 534 IBS cases and 4,932 
asymptomatic controls from TwinGene, a subset of the Swedish Screening Across the 
Lifespan Twin study (SALT),195, 196 where heritability of IBS has been previously estimated 
to be 25%.197 Suggestive regions of association were detected in the GWAS and were further 
replicated in six independent clinical case-control cohorts from Europe and the US 
(replication total n=3,511) (figure 8). One of these loci showed consistent effect on IBS risk 
in all of those study populations (meta-analysis p=9.31×10-6); a locus on chromosome 7 
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harboring the genes KDELR2 (KDEL endoplasmatic reticulum protein retention receptor 2) 
and GRID2IP (glutamate receptor, ionotropic, delta 2 interacting protein). Even though no 
association signal reached genome-wide significance (total sample size of 8,977 likely still 
not big enough), this study served as a proof-of-principle pilot GWAS and corroborated our 
hypothesis that there lies a great potential in utilizing large general population-based cohorts 
with available genotype and healthcare/epidemiological data for the purpose of discovering 
IBS risk genes.180 
 
Figure 8. Forest plot showing the association between IBS and the lead SNP (rs12702514) of a 
suggested IBS risk locus on chromosome 7. Individual and cumulative ORs and 95% confidence 
interval are shown together with sample size for the discovery cohort TwinGene (part of SALT), each 
replication cohort, and the total study cohort. GWAS, genome-wide association study; OR, odds ratio; 
SALT, Screening Across the Lifespan Twin study. Ek et al.,180 © see page 71. 
In paper IV, we continued on this approach by combining five independent GWA studies 
from cohorts around Europe (namely LifeLines-DEEP, SHIP-Trend, TwinsUK, the Northern 
Finland Birth Cohort 1966, and TwinGene) and combined the summary statistics from these 
GWASs in a large meta-analysis involving a total of 1,335 IBS cases and 9,768 controls.  
Excitingly, this way of ‘thinking outside the box’ has grown into a large collaborative 
ongoing project named the bellygenes initiative (www.mdalab.org/bellygenes), which is led 
by PI Mauro D’Amato and co-PI Alexandra Zhernakova. Through international 
collaboration, this project has received increased interest, and finally a large number of 
general (European population-based cohorts) and dedicated (IBS case-control samples from 
expert clinics in Europe and the US) resources have been gathered that enable studies of IBS 
genetic architecture with unprecedented potential.  
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2 AIMS OF THE THESIS 
2.1 OVERARCHING HYPOTHESES 
Based on available and recent evidence in the IBS research field, we believe that: 
• IBS is a constellation of disorders with similar symptoms but possibly different 
underlying pathophysiological mechanisms. 
• Genetic predisposition contributes to IBS. 
• The genetic background for most IBS patients is complex and polygenic with many 
genetic variants together contributing to disease.  
• Smaller subgroups of IBS exist where rare highly penetrating single gene variants 
may principally account for their GI symptoms. 
2.2 AIMS 
The overall aim of this thesis was to identify, validate and functionally characterize genetic 
factors predisposing to IBS and its associated gastrointestinal symptoms and intermediate 
phenotypes. However, as IBS genetic research is still in its infancy due to a complex and 
heterogeneous phenotype that is extremely challenging to study, the scope of the thesis has 
mainly focused on the discovery of IBS risk genes and variants. The ultimate goal with our 
research is to identify key pathophysiological mechanisms that can help explain the etiology 
of IBS and improve diagnosis and the classification of disease subtypes, eventually leading to 
the delineation of novel and personalized therapeutic options. We strive to do so by adopting 
different methodological approaches, with the following specific aims: 
• Candidate-gene studies, with a hypothesis-driven approach to evaluate the role of a 
specific gene or set of genes that may play a role in IBS pathophysiology (paper I, II 
and III). 
• Large-scale analyses, i.e., genome-wide association studies (GWAS) and their meta-
analyses to capture common, low-penetrance gene variants contributing to IBS in the 
general population (paper IV). 
• Targeted analyses, including focused genotyping of case-control cohorts for 
validation of GWAS findings (paper II), as well as searching for rare, high-
penetrance variants in specific genes (paper III). 
• Functional characterization of identified risk genes and variants (paper III).  
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3 METHODS AND MATERIALS 
To facilitate better understanding for the reader of why and how our group performs genetic 
studies on IBS, relevant concepts, methodologies and our approach have been described 
already above, embedded in the section 1.5 (Genetics of IBS) in relation to previous work and 
the challenges that this complex phenotype poses.  
Specific descriptions of the methods and materials used in the studies included in this thesis 
are fully described in the corresponding papers I–IV and related supplementary information.  
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4 RESULTS AND DISCUSSION 
This section provides a summary of the main findings of this thesis, together with 
interpretation and discussion of results. For further information, see corresponding papers. 
4.1 PAPER I 
NPSR1 polymorphisms influence recurrent abdominal pain in children: a population-
based study. 
Recurrent abdominal pain (RAP) is the cardinal symptom of IBS and occurs frequently in 
children.198-200 Compared to the adult classification system for FGIDs (Rome III), where 
subgrouping is based on anatomical location of the main symptoms, pediatric FGIDs are 
instead grouped based on predominant symptom type.201 In children/adolescents, IBS is 
found in the group of ‘abdominal pain-related FGIDs’.202 Mechanisms and the genetic 
background of visceral sensation and pain are largely unknown, but among others, proposed 
candidate genes include different neurotransmitters and their receptors.74 As described above 
(1.5.5), previous evidence suggests neuropeptide S and its receptor (encoded by the NPSR1 
gene) to be involved in nociception,181, 182 and in addition to the brain, NPSR1 expression has 
been reported in enteroendocrine cells in the gut.186 Previous work from our group has shown 
association of NPSR1 polymorphisms with colonic transit and sensory ratings, and also 
demonstrated induced expression of other neuropeptides and gut hormones upon NPS-
NPSR1 signaling in vitro.77, 186 Hence, this gene was a plausible candidate to investigate 
further for its potential genetic association also with abdominal pain.  
In paper I, we sought to determine whether NPSR1 genetic variability influences RAP 
presence in children, and exploited data from the Swedish birth cohort BAMSE (Children 
Allergy Milieu Stockholm and Epidemiological Study).203 For the purpose of the study, a 
total of 1,744 children with available genotype and phenotype data were included, and after 
quality control checks 1,556 samples could be included in the association analysis. Twenty-
eight single nucleotide polymorphisms (SNPs) were used to test NPSR1 for association with 
recurrent abdominal pain (RAP) using logistic regression under an additive genetic model, 
adjusted for sex, asthma and parents' country of origin. Phenotypic information was derived 
from questionnaires filled in at 12 years of age, and RAP was defined as recurrent abdominal 
pain occurring at least once a month. The prevalence of RAP was 9% in the study sample, 
with significantly more girls (70%) than boys (30%) affected (p=0.0001). Seven NPSR1 
SNPs were significantly associated with RAP, five of which withstood false discovery rate 
(FDR) correction for multiple testing (best p=0.00054, FDR corr. p=0.014, OR:1.55 for 
rs2530566). The 28 tested variants span over the entire (~220 kb) NPSR1 gene, and the 
associated SNPs are all non-coding and map in a putative regulatory region upstream of the 
gene; hence, these may potentially exert their genetic effects through modulation of NPSR1 
(mRNA) expression. In line with this hypothesis, inspection of ChIP-seq data from the 
Encyclopedia of DNA Elements (ENCODE) showed dense binding of transcription factors at 
this locus, including STAT3, CEBPB, c-Fos and others. 
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Although expression of NPSR1 is absent or extremely low in most human tissues, mRNA 
expression in several brain areas has been documented, such as the hypothalamus and 
amygdala.204, 205 To further characterize potential functional consequences of NPSR1 genetic 
variation of the top associated SNP (rs2530566), we inspected publicly available mRNA 
expression data from the Genotype-Tissue Expression project (GTEx; wwwgtexportal.org) to 
look for correlations between NPSR1 genotype and mRNA expression (eQTLs) in relevant 
tissues. Interestingly, a significant correlation between RAP-risk allele G and NPSR1 mRNA 
expression was detected in the brain region amygdala (p=0.03). This is a potentially 
important observation since amygdala not only plays a key role in emotions and affective 
states such as anxiety, depression and response to fear, but also seems to be highly involved 
in pain modulation and perception.206 Interestingly, studies in rats suggest NPS to have pain-
inhibiting effects through mechanisms in the amygdala.206-208  
The NPSR1 gene was originally described as the GPRA (G protein-coupled receptor for 
asthma susceptibility) or GPR154, since it encodes for an, at that time, orphan receptor 
associated with asthma and related traits.187-190 However, there is also evidence of a role of 
this receptor and its signaling in anxiety;183, 184 a well-known comorbidity of asthma in young 
people,209 but also of RAP.210 In the current study, we were not able to use anxiety as a 
covariate, since data on this had only been collected at 8 years and not 12 years in BAMSE. 
However, we note that previous association between NPSR1 and anxiety in the BAMSE 
cohort did not involve the same SNPs or haplotype as in our current study on RAP,183 
suggesting that the association with RAP is independent from that of anxiety.   
The mechanisms and pathways behind pain perception are complex.62 Visceral pain stimuli 
are sensed by nociceptors in the ENS, which transmit the information up to the CNS, but the 
sensation can also be inhibited or facilitated on different levels along the brain-gut axis 
through endogenous pain modulation involving various neurotransmitters, hormones and 
their receptors. In addition to a direct involvement in pain modulation in the brain, there are 
several other ways in which genotype-driven NPSR1 changes (presumably expression levels) 
may potentially affect visceral pain (figure 9), as described more in detail in the discussion of 
paper I. One potential way could be through other neuropeptides and hormones, as previous 
work has shown that NPS-NPSR1 downstream signaling in an in vitro model can induce the 
expression of a number of gut hormones and neuropeptides including neurotensin, 
cholecystokinin, vasoactive intestinal peptide and somatostatin.77, 186 Several of these have 
gut motor and secretory functions but some are also involved in pain modulation. Moreover, 
NPSR1 polymorphism is associated with chronic inflammatory diseases such as IBD191 and 
rheumatoid arthritis,192 and higher mRNA levels have been observed in inflammation 
(IBD),191 activated macrophages and T lymphocytes,185 and THP-1 monocytic cells upon pro-
inflammatory cytokine stimulation.186 At the same time, antinociceptive effects have been 
demonstrated from NPS-NPSR1 signaling in inflammatory pain models in mice.182 Hence, a 
role of NPSR1 in inflammation may not only be a plausible explanation for the genetic 
associations with inflammatory diseases and asthma, but may also be of relevance for visceral 
pain and the association with RAP.  
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Figure 9. Schematic model for NPSR1 involvement in inflammation, gut-brain communication and 
visceral pain. Increased NPSR1 signaling induces the expression of various gut hormones and 
neuropeptides, and could directly or indirectly affect inflammatory responses and gut motor and 
sensory functions. CNS, central nervous system; ENS, enteric nervous system; NPS, neuropeptide S; 
NPSR1, neuropeptide S receptor 1. Reproduced from paper I, © see page 72. 
The main limitation of the current study is the relatively small case sample set (159 RAP 
cases, 1,582 controls), which did not allow us to do NPSR1 haplotype analyses because of 
insufficient statistical power. It is therefore difficult to conclude exactly which SNP or 
combination of variants is responsible for the observed association with RAP. In addition, our 
definition of RAP (1/month) does not exactly match that of Apley211 or Rome III,202 but the 
prevalence of 9% in our study is similar to that reported based on those definitions.200, 211, 212 
To confirm our results, replication and further investigations are encouraged in independent 
larger cohorts, and future studies should also investigate NPS variants and gene-gene 
interaction effects, since interaction of NPS and NPSR1 variants have recently been 
demonstrated in the same cohort for asthma.213  
In conclusion, in paper I we report on the involvement of NPSR1 SNPs in the presence of 
RAP in 12-year-old children. Further studies are warranted to investigate the specific 
mechanism(s) in which NPSR1 and its signaling influence abdominal pain in FGIDs.  
4.2 PAPER II 
TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M. 
As described in 1.5.5 above, previous work from our group in collaboration with G. 
Farrugia's team at the Mayo Clinic showed that 2.2% of IBS patients carry functionally 
relevant mutations in the ion channel gene SCN5A, and common SNPs also showed 
association in our published GWAS of IBS (also described in 1.5.5).56, 180 Since many ion 
channels are involved in mechanisms of visceral sensation and GI motility,78 we 
hypothesized that also other ion channelopathies may be implicated in IBS pathophysiology. 
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For this purpose, association results from our GWAS180 were inspected at genetic locations 
for 27 ion channel genes selected from similar functional pathways related to GI function (gut 
motility and visceral sensation among others, see supplementary information to paper II). 
This resulted in the detection of nominally significant (uncorrected p<0.05) association for 
four genes: transient receptor potential channels TRPV3 and TRPM8, and the calcium 
voltage-gated channels CACNA1A and CACNA1E. These genes were brought out for 
replication and 33 tagging SNPs were selected from their loci and genotyped in an 
independent Swedish multicenter cohort of 386 clinical IBS cases (Rome III) and 357 
controls. Sex-adjusted logistic regression analysis in this replication set detected significant 
associations for TRPM8 exclusively in the constipation-predominant IBS subtypes (best 
p=3.9×10-5; OR=1.94 for rs2362290 with IBS-C and IBS-M combined), and meta-analysis of 
GWAS and replication data (totaling 920 cases and 5,289 controls) yielded strongest 
evidence of association (testing IBS overall) with no statistical heterogeneity and same 
direction of effects in the two studies.  
The two SNPs showing strongest association and IBS risk effect in IBS-C/M map to the 
promoter region of the gene where the minor alleles associated with increased risk of IBS in 
our Swedish case-control samples. Hypothesizing that these promoter SNPs may exert their 
function through changes in expression levels, in silico analyses were performed, which 
predicted these two SNPs to alter transcription factor binding to DNA. Gene-set enrichment 
analysis (using EnrichR) of affected transcription factors yielded several significantly 
enriched pathways and ontologies including ‘abnormal hepatobiliary system’, and additional 
analyses also showed that TRPM8 co-expressed genes are enriched in pathways related to 
bile acid/salt secretion and transport. These observations are of potential importance since 
bile acid metabolism/synthesis has been implicated in IBS,51, 122 and bile acids or IBAT (the 
re-uptake transporter) inhibitors may be used for the treatment of constipation.214  
Furthermore, the Population-based Colonoscopy study (PopCol) was exploited for 
investigating the relationship between TRPM8 genotype and GI motility, by using stool 
consistency (based on Bristol Stool Form Scale [BSFS] scores from diaries) as surrogate 
measurement of intestinal transit time. This revealed TRPM8 IBS-C/M risk alleles to be 
consistently associated with harder stools (lower BSFS scores), suggesting that these variants 
have constipation related effects. 
The transient receptor potential cation channel melastatin 8 (TRPM8), or the ‘cold and 
menthol receptor’ (CMR1), is activated by cool temperatures from 8°C to ~28°C, covering 
both innocuous cool and noxious cold (<15°C) ranges (figure 10). Cooling compounds such 
as menthol, spearmint and icilin also activates the channel.215 Cooling of the skin is a 
common strategy to ease pain, and it is believed that this cool-induced analgesia is mediated 
by TRPM8 in a ‘gate control’ mechanism (which implies that a nociceptive pain signal can 
be suppressed by an innocuous stimuli in the synaptic region of the dorsal horn).216, 217 
Interestingly, the herbal preparation peppermint oil is frequently used in IBS therapy and has 
shown to be superior to placebo in the improvement of global IBS symptoms and in 
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particular abdominal pain.218 The major constituent of peppermint oil, menthol (a TRPM8 
agonist), seems to have both antispasmodic (smooth muscle relaxing) and pain modulation 
properties, although underlying mechanisms are unclear.136, 137 The TRPM8 channel appears 
to be implicated in visceral hypersensitivity,82 and expression on sensory neurons innervating 
visceral organs, including colon, has been reported,219 but its functions and effects do not 
seem that straightforward. Studies on experimental pain and knock-out models in mice have 
demonstrated both analgesic effects and increased pain responses from TRPM8 
stimulation,220, 221 and a role in colonic inflammation is also suggested.82 Moreover, co-
expression and cross-talk between TRPM8 and two other ion channels implicated in IBS and 
visceral sensation (TRPV1 and TRPA1) have been shown, and it seems like TRPM8 can 
inhibit their downstream chemo- and mechanosensory signaling in colonic afferent fibers 
through cross-desensitization.219 Thus, taken together, TRPM8 may not only play a function 
in innocuous cool sensation but also in nociception as well as analgesia, depending on 
location and context, and it is possible that interactions and sensitizations of different TRP 
channels, triggered by an inflammatory state, contribute to and modulate visceral pain and 
hypersensitivity.82 These TRP channels therefore represent promising drug targets for the 
relief of chronic pain conditions, including IBS.82, 222  
 
Figure 10. The transient receptor potential cation channel melastatin 8 (TRPM8) is the ‘cold and 
menthol receptor’ activated by both innocuous cool and noxious cold temperatures (ranging from 8°C 
to ~28°C), as well as cooling compounds such as menthol (structure shown in figure), spearmint and 
icilin. © See page 72 (mint leave). 
The strengths with our paper II is the observed evidence of association in two independent 
study cohorts (discovery GWAS and replication case/control) that showed no statistical 
heterogeneity and same direction of effects, and the large sample size (total n=920 cases and 
n=5,289 controls). The association was stronger in the IBS-C/M group while absent in IBS-
D, which suggests the genetic effect may be linked to constipation. This was also supported 
by the correlation between IBS risk alleles and harder stools (lower mean BSFS scores) in a 
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general population-based cohort. The definition of IBS used in the TwinGene population 
(GWAS) showed 99% concordance and high reliability (κ=0.92) with Rome II criteria.197 
However, subgrouping according to the Rome criteria was not possible with the questions 
available in the TwinGene study questionnaire. Thus, subgroup analysis in our study was 
only performed on the replication data set.  
The signal of association between TRPM8 gene and IBS detected in our study is contained in 
an upstream region of the gene and only includes non-coding variants. Two of the strongest 
IBS-C/M associated SNPs map to the gene promoter, hence, we hypothesized that their 
functional effect on the phenotype may be mediated through altered transcriptional control, 
which was also supported by the computationally predicted change from these variants in 
transcription factor binding affinity. However, these SNPs are in complete LD with each 
other and in complete or high LD with also other highly significant variants. Hence, to 
conclude exactly what are the causing variant(s) responsible for the association with IBS, 
further investigation will be needed. Of note, it is still highly possible that also rare coding 
variants may be of importance in certain subgroups of patients. Thus, similar to the case of 
SCN5A,56 the TRPM8 gene represents an ideal candidate for targeted sequencing efforts to 
search for rare mutations that may have a direct effect on channel function in IBS. 
Taken together, in paper II we provide evidence of an association between TRPM8 gene 
polymorphisms and increased risk of IBS with constipation (IBS-C and -M), and also observe 
risk alleles to correlate with lower BSFS scores (indicating slower transit time). Although 
further studies are warranted to evaluate causative SNPs and potential rare contributing 
variants, this finding adds to the increasing evidence of ion channel involvement in IBS 
pathophysiology, and may contribute to improved therapeutic precision in subsets of patients.  
4.3 PAPER III 
Functional variants in the sucrase-isomaltase gene associate with increased risk of 
irritable bowel syndrome. 
Nutrition and dietary factors are receiving increased attention in IBS. For many IBS patients, 
food, and in particular carbohydrates, are well-recognized symptom triggers, post-prandial 
symptoms are common, especially in IBS-D, and patients tend to avoid foods perceived as 
problematic.99-102, 104 Of note, carbohydrate restrictive diets have proven effective in reducing 
symptoms in subgroups of patients,111, 223 and it has been suggested that at least some 
individuals with IBS (primarily postprandial IBS-D) may in fact suffer from carbohydrate 
maldigestion due to deficiency of digestive enzymes.101 
Sucrase-isomaltase (SI) is a digestive brush-border enzyme in the small intestine, crucial for 
the breakdown of starch and sucrose in the final step of human digestion (figure 11 and 4, 
page 13).106 In congenital sucrase-isomaltase deficiency (CSID), a rare genetic condition also 
called sucrose intolerance, mutations in the SI gene result in reduced or absent sucrase and/or 
isomaltase enzymatic activity.224 Consequently, non-digested sucrose and partly digested 
starch accumulate in the intestinal lumen of these patients, who will present with osmotic  
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Figure 11. The role of sucrase-isomaltase (SI) and SI deficiency in starch and sucrose digestion. SI is 
essential for the breakdown of dietary starch and sucrose. In the brush-border of the small intestine, SI 
(as well as maltase-glucoamylase, not shown here) hydrolyzes α-1,4-glycosidic bonds in products of 
α-amylase (α-A) starch digestion. Isomaltase can also break the branching α-1,6-glycosidic bonds in 
isomaltose and α-limit dextrins, and sucrase hydrolyzes sucrose into glucose and fructose. In a normal 
state, monosaccharides are readily absorbed in the small intestine. In SI deficiency, accumulation of 
sucrose and partly digested (unabsorbed) starch occurs. These molecules are osmotically active, 
causing water retention into the lumen, and are fermented by colonic bacteria producing gas. This 
results in distention and increased motility, and symptoms of diarrhea, abdominal pain and bloating.  
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diarrhea, abdominal pain and bloating (due to colonic fermentation), —symptoms very much 
similar to those of IBS and chronic diarrhea. While most CSID cases are detected early in life 
with severe enzyme deficiencies typically caused by homozygous or compound heterozygous 
SI mutations,225, 226 the phenotype and severity of symptoms show large variations and onset 
later in life has also been reported.227, 228 This speaks for a potentially higher clinical impact 
of SI genetic variations than previously thought, and the presence of a wide range of 
conditions from severe to milder forms.229, 230 Therefore, we hypothesized that SI mutations 
and/or functionally defective polymorphisms, may be relevant in IBS, in particular diarrhea. 
Paper III is a multidisciplinary study where we strived to test the potential relevance of SI 
genetic variants in IBS by conducting a series of experiments and association analyses. A 
schematic representation of SI protein structure and the positions of the studied genetic 
variants are displayed in figure 12 below, together with the key results of the study. First, 
sequencing of the SI coding region was performed in four IBS-D families including seven 
post-prandial IBS-D cases and one asymptomatic relative. No new SI mutations were 
identified in this effort, and all sequenced family members were homozygous for reference 
alleles of all common (MAF >0.01) coding (missense) SNPs, except at two sites; p.Val15Phe 
(rs9290264) and p.The231Ala (rs9283633). Since these, together with p.Met1523Ile 
(rs4855271), represent the only common coding SNPs in the SI gene, in silico analyses were 
performed to evaluate their potential deleterious effects. Based on computational predictions 
(PHRED-like scores from the Combined Annotation-Dependent Depletion [CADD] 
database)231 the p.Val15Phe SNP was ranked among the top 1% most deleterious amino acid 
substitutions in the human genome (similar to that of CSID mutations), whereas the other two 
were predicted to be benign. The p.Val15Phe, which is fairly common in the general 
population (MAF 28% in EUR), was detected in 6/7 affected probands and segregated with 
IBS in the two families where SI sequence data of parents also were available.  
Furthermore, in vitro experiments using COS-1 cells transfected with SI coding vectors with 
either Val or Phe at residue 15 provided evidence for this SNP to be functionally relevant, 
demonstrating the alternative 15Phe variant to be 1) 43% less associated with lipid rafts, 2) 
20% less localized to the cell surface, and 3) corresponds to a 35% reduced SI enzymatic 
activity, compared to 15Val. These results make sense, since the p.Val15Phe is located in the 
stalk region of the protein, where it is highly plausible that the substitution of the aminoacid 
valine with a bulky phenylalanine in the first α-helix of this transmembrane domain may have 
an impact on the way SI associates with membranes. Consequently, fewer enzymes will end 
up on the cell surface of the enterocytes and SI enzyme activity overall will be impaired.  
Next, together with the four most well known CSID mutations,232 the p.Val15Phe SNP was 
genotyped in a multicenter cohort of 1,031 IBS cases and 856 controls from clinical centers 
in Europe and USA (all unrelated, and of self-reported European ancestry/’white’). Results 
revealed that CSID mutations were found more often in IBS patients than controls (2.13% 
and 1.27%, respectively, p=0.074; OR=1.84), and this finding could be consolidated by 
inspecting publicly available data from a large reference panel of >30,000 sequenced 
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European (EUR) individuals from the Exome Aggregation Consortium (ExAC 
[http://exac.broadinstitute.org]) (p=0.02; OR=1.57). Interestingly, in the case-control sample, 
the polymorphism p.Val15Phe significantly associated with diarrhea-predominant IBS 
(p=0.00051, OR=1.34, IBS-D and IBS-M combined) whereas no association was detected for 
IBS-C (p>0.05). This finding goes well in line with our hypothesis that if SI deficiency were 
present in IBS, it should be of relevance primarily for diarrhea-predominant phenotypes.  
 
Figure 12. Schematic representation of sucrase-isomaltase (SI) protein structure and functional 
domains, together with the key results obtained in paper III. The position of the four congenital SI 
deficiency (CSID) mutations and the common coding SI polymorphisms are reported and color-coded 
according to their functional effects. SNP, single nucleotide polymorphism. Modified figure from 
paper III, © see page 72. 
Finally, data from the general population-based study PopCol were exploited for pilot tests to 
investigate the p.Val15Phe variant in relation to IBS status, bowel function and microbiota 
composition in the general population. Although sample size was small (30 cases identified 
by Rome III in questionnaires, and 163 asymptomatic controls), 15Phe was significantly 
associated with IBS risk, in particular IBS-M (p=0.017, OR=3.81) and further strengthened 
the association with IBS-D/M when combined with the case-control results (p=0.00012, 
OR=1.36). Furthermore, diary data (totally 3 weeks daily recordings of stool patterns and gut 
symptoms) from 133 PopCol individuals indicated the 15Phe allele to correlate with 
increased stool frequency (p=0.026). Last, by testing the 20 most abundant genera in feacal 
microbiota data from 136 PopCol individuals, an inverse correlation was detected between 
the abundance of Parabacteroides and the number of 15Phe alleles (p=0.0024). Although this 
finding will have to be confirmed and we cannot draw any conclusions yet on a cause-effect 
relationship, it is interesting since Parabacteroides belong to the Bacteroidetes phylum and 
appears to be underrepresented in IBS, at least as reported in some studies.88-90, 233 
Taken together, the results from paper III suggest that SI deficiency, although partial or in a 
milder form, is present in a subset of patients with IBS who carry heterozygous SI mutations. 
CSID	mutations	with	known	SI	defects	
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Common	coding	SNP	
Strongly	associated	with	IBS	(especially	-D	and	-M)	
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Through a series of experiments and tests, we also provide evidence of a potential role of the 
common coding polymorphism p.Val15Phe, which significantly associates with increased 
risk of IBS, especially in the presence of diarrhea, and is functionally relevant as 
demonstrated in silico and in vitro with 35% reduced enzymatic activity. We thereby provide 
a plausible explanation of a link between carbohydrate consumption, gut microbiota and gut 
symptoms in a subset of IBS patients genetically predisposed to SI deficiency (figure 13).  
 
Figure 13. Interplay between genetic variation, carbohydrate consumption and gut microbiota 
activity. SI genetic variants may explain IBS symptoms in a subset of patients by predisposing to 
milder forms of SI deficiency. © See page 72. 
The major strength with our study is the multi-disciplinary effort, where we have tried to 
approach our hypothesis through different levels of investigation, including sequencing in 
affected families, in vitro functional characterization, association analyses in four 
independent case-control cohorts, and additional pilot studies of relevant (intermediate) 
phenotypes in a general population-based cohort. The findings from these different levels of 
investigation all point to the same conclusion that SI genetic variation seems to play a role in 
IBS. In our combined case-control sample, the functionally relevant polymorphism 
p.Val15Phe showed strong association with IBS-D and IBS-M, and in the same study 
population we could also observe an almost twofold increased risk of IBS in heterozygous 
carriers of rare known CSID mutations (any of the four variants found in 2.13% of cases vs. 
1.17% of controls). Although this finding was statistically weak, likely due to control sample 
size (n=1,031) inadequate to test very rare mutations, we could statistically consolidate this 
difference by comparing with the prevalence in the general population (>30,000 EUR 
individuals from ExAC), where the cumulative prevalence of these mutations was 1.37%.  
Of note, this particular approach of using ExAC data as a comparison group has recently been 
expanded in a follow-up study from our group (published online Feb 2018, not included in 
this thesis).234 In that study, a two-step computational and experimental strategy was used to 
determine whether also other (dys)functional SI variants increase the risk of IBS. First, 
SI variants Carbohydrates 
Gut microbiota 
IBS 
symptoms 
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computational tools were used to identify clinically relevant mutations based on predicted 
pathogenicity scores, and a total of 880 functionally deleterious variants were identified. 
Thereafter, inspection of Illumina HumanCoreExome data for 2,207 IBS cases from the large 
ongoing bellygenes initiative (www.mdalab.org/bellygenes) project identified high-quality 
genotype data for 46 of these variants, and 17 of those were found in at least one IBS carrier 
and also in a reference population (n=33,370) of European ancestry from ExAC. These 17 
mutations were found significantly more often in IBS cases than in the reference population 
(p=0.00049; OR=1.45), with a cumulative prevalence of 4.2% in IBS-D and 4.5% in IBS-C 
compared to 2.8% in reference controls. Hence, that study supports the results of paper III 
and provides further evidence of the prevalence of functionally deleterious SI variants in IBS.  
To understand the specific roles of SI variants in IBS, functional characterization studies in 
vitro are valuable, and as recently shown by Gericke et al.,235 different SI mutations have 
different biochemical and functional consequences and these authors again conclude that a 
spectrum appears to be present with mild to severe forms of SI deficiency. Future studies 
should also aim to investigate the combined effect of risk alleles, as it is possible they 
influence IBS through different combinations (homozygous, heterozygous or compound 
heterozygous). Moreover, our results provide a rationale for studies investigating the 
interplay between carbohydrate consumption, gut microbiota and genetic defects of involved 
enzymes (SI or other), as well as studies evaluating the effect from dietary modifications or 
enzyme supplements in IBS stratified by SI genotype. Interestingly, in another recent study 
from our group (published online Jan 2018, not included in this thesis),236 utilizing two large 
German population-based cohorts (total n=1,398), the association of SI p.Val15Phe with IBS 
was confirmed (3.69% of 15Phe carriers reported IBS compared to 1.84% of non-carriers; 
p=0.044; OR=2.04) and preliminary evidence was provided on SI genotype-carbohydrate-
microbiota interactions. The difference in IBS prevalence between 15Phe carriers and non-
carriers was most pronounced in low-starch consumers (estimated from food frequency 
questionnaires); 7.8% vs 1.9%, p=0.029; OR=4.17. Furthermore, correlation between starch 
intake and microbiota composition could be observed (p=0.007), and this effect seemed to be 
dependent on p.Val15Phe genotype. Interestingly, taking into account also IBS status, feacal 
microbiota abundance of Blautia (known as a ‘carb-digester’) was significantly higher in IBS 
than non-IBS in the 15Phe carrier group (p=0.00041) whereas no difference could be seen in 
those who did not carry the 15Phe genotype (p=0.31).  
To conclude, similar to lactose intolerance often presenting as IBS until diagnosis is 
established, milder forms of SI deficiency may be missed in this type of patient group and 
possibly misdiagnosed as IBS if not tested for. The results from paper III and others 
mentioned above should contribute to increased awareness of this condition as a potential 
underlying cause of IBS and similar FGIDs. As we learn more about the functional effects of 
SI genetic variants and their contributing role in gut symptoms, this information holds 
potential for eventually stratifying patients and making it possible to direct personalized 
treatment (i.e., dietary modifications and enzyme replacement therapy) in those with 
genetically derived SI deficiency.  
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4.4 PAPER IV 
A GWAS meta-analysis from five population-based cohorts implicates ion channel genes 
in the pathogenesis of irritable bowel syndrome. 
As described in section 1.5 (Genetics of IBS) above, previous studies on the genetics of IBS 
have been focused on single genes in hypothesis-driven approaches conducted in relatively 
small case-control sample sets, and most of the findings have not been adequately replicated 
in independent cohorts. The complex and heterogeneous phenotype of IBS poses significant 
challenges for those trying to decipher its genetic background, and in order to overcome some 
of those challenges we recently proposed an alternative strategy for IBS gene discovery. This 
strategy means we shift gear to a general population-based approach exploiting existing 
genetic and epidemiological data from large cohorts for the purpose of performing large-
scale, hypothesis-free IBS genome-wide association studies (GWAS) and their meta-
analyses, and has been further introduced in 1.5.5 above and in our reviews from 20134 and 
2016.5 This way of approaching the challenging task of exploring the genetic architecture of 
IBS had not been attempted before, and following our proof-of-principle pilot GWA study 
conducted in the Swedish TwinGene cohort,180 we continued this work by combining it with 
additional independent GWA studies from Europe in a large meta-analysis of IBS. 
In paper IV, we utilized data from five large epidemiological population-based cohorts, 
namely TwinGene (Sweden), LifeLines-DEEP (The Netherlands), Study of Health in 
Pomerania (SHIP)-Trend (Germany), TwinsUK (UK) and the Northern Finland Birth Cohort 
1966 (NFBC1966, Finland), together comprising a set of 18,659 individuals with available 
genotype and phenotype data. Short descriptions of these cohorts are provided in the method 
section of paper IV with related references. Imputation and quality control (QC) of data was 
carried out at respective sites for each cohort, followed by individual GWASs using sex-
adjusted logistic regression under an additive genetic model. By using questionnaire data 
compatible with Rome III criteria, a total of 1,335 IBS cases (74.8% females) and 9,768 
asymptomatic controls (55.6% females) were identified in these five cohorts. For details on 
methods and computational strategy, please see paper IV with supplementary information. 
However, an overview of the study steps is provided in figure 14. Due to ethical restrictions 
in individual level genotype data sharing, QC and GWA analyses for three of the cohorts 
were run locally by collaborators, whereas two datasets (TwinGene and SHIP-Trend) were 
run by us at KI. Following the GWASs, summary statistics were quality controlled, 
harmonized and combined in a meta-analysis using the fixed-effect model weighted by 
inverse-variance. Finally, a total of 2,483,385 high-quality SNP markers could be included in 
the meta-analysis (passing QC and with summary statistics available from at least two 
datasets).  
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Figure 14: Flowchart of the study steps in paper IV. NFBC1966, Northern Finland Birth Cohort 1966; 
SHIP, Study of Health in Pomerania; LL, LifeLines. 
Although no genetic marker reached genome-wide significance (p≤ 5.0×10-8) in either 
individual GWASs or the meta-analysis (figure 15), suggestive association signals  
(p≤ 5.0×10-6) were detected for seven genomic regions/loci in the meta-analysis with 
concordant genetic risk effects across studies. These loci together harbour a total of 35 genes 
that physically map to the regions. Worthy of mention among these genes is the SCN1B gene 
located in a suggestive risk locus on chromosome 19 and which interestingly codes for a β-
subunit of the NaV1.5 ion channel. As described in the introduction, the α-subunit of the same 
channel is encoded by the SCN5A gene, in which missense mutations have been identified in 
2.2% of IBS patients.56 Both SCN1B and SCN5A have been implicated in cardiac arrhythmia 
syndromes, such as Brugada syndrome,237 hence SCN1B represents a plausible candidate IBS 
risk gene and deserves attention in follow-up studies. Moreover, the same loci also contains 
other potentially interesting genes, including FXYD(Phe-x-Tyr-Asp)-domain containing ion 
transport regulators (FXYD1, FXYD3, FXYD5 and FXYD7), which interact with and regulate 
the function of ion transporters such as the Na+/K+-ATPase in a tissue-specific manner, 
affecting for example neuronal excitability or muscle contraction.238  
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Figure 15: Manhattan plot of IBS GWAS meta-analysis results. Red horizontal line: genome wide 
(p=5×10-8) significance level. Blue horizontal line: suggestive (p=5×10-6) significance level. For each 
suggestive association signal, the nearest gene (mapping closest to the lead SNP) is reported, together 
with the number of additional genes from the same locus (in brackets). Reproduced from paper IV,  
© see page 72. 
As seen in figure 16, the expression of most of the genes (27/35) located in the seven 
suggestive IBS risk loci (including SCN1B and the FXYD genes mentioned above) appears to 
be influenced by genetic variation in these regions (defined as cis-eQTLs), as well as an 
additional 29 nearby genes (identified from screening the GTEx database, version v6),153 
thereby totaling 64 potential IBS risk genes from this meta-analysis. This set of 64 candidate 
IBS risk genes was brought forward for further functional annotation in order to get 
preliminary biological insights from the observed associations using in silico computational 
tools. First, tissue-specific enrichment analysis (TSEA) results indicated higher expression 
(nominally significant p=0.027) of these genes in the colon compared to other tissues. 
Second, gene-set enrichment analysis (GSEA) returned strongly significant results for Gene 
Ontology (GO) terms of ion channel activities (both at the molecular function and biological 
process levels), which means that the 64 candidate IBS risk genes from the 7 most associated 
regions are enriched in ion channel related pathways. This finding is especially noteworthy 
since it reinforces and adds on to previous evidence from our group and others that suggests 
ion channel genetic variation and ion channel function contribute to IBS risk and its 
intermediate phenotypes (e.g., SCN5A,56 TRPM8 (paper II) and the GWAS of stool 
frequency).84 Intriguingly, ion channel activity has recently been highlighted once again in an 
even larger GWAS of IBS (although using an alternative definition; self-reported doctor’s 
diagnosis) conducted by our group, utilizing data from the UK Biobank (see further info 
below).239 Moreover, in our GSEA downstream analysis of GWAS meta-analysis results, an 
alternative functional classification was also used; the Molecular Signatures Database (see 
methods in paper IV). Again here the ion channels category returned most significant, 
although together with enrichment of genes also in the Liver genes - metabolism and 
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xenobiotics category. This is notable since both of these biological pathways were also 
highlighted in the GWAS of stool frequency mentioned above.84 
Figure 16: Summary of post-GWAS analyses based on IBS GWAS meta-analysis results. For 
explanation, see the text. eQTL, expression quantitative trail loci.  
While conducting this, —so far the largest—, meta-analysis of IBS GWASs, we sought to 
also verify whether any of the IBS candidate risk genes previously reported in the literature 
show association in this data. Therefore, meta-analysis results were inspected in relation to 18 
selected loci previously proposed to affect IBS risk or its intermediate phenotypes. Nominal 
significance (at least one SNP marker with p<0.05) was detected at 12 of these loci, with best 
evidence of replication from the KDELR2/GRID2IP locus (7p22.1 region detected and 
replicated in our pilot GWAS),180 and the genes SCN5A, NPSR1, TRPM8 and SI (figure 16). 
While association at the KDELR2/GRID2IP, SCN5A and TRPM8 was expected since these 
were originally detected in the TwinGene sample, which largely contribute to the current 
meta-analysis, the signals from NPSR1 and SI may represent bona fide replications. 
Considering the subtype specific effects detected for, among others, TRPM8 in constipation-
predominant IBS (paper II) and SI in diarrhea-predominant IBS (paper III), it would have 
been interesting to further test the association stratified by subtypes also in the current data. 
However, this was not possible as the specific questions needed for classifying subjects into 
Rome III defined IBS subtypes were not included in the questionnaires from all of the five 
cohorts. However, future studies are encouraged to investigate also subtype-specific effects. 
Our previously published pilot IBS GWAS in TwinGene180 and this meta-analysis of five 
GWASs represents important progress in the gene-hunting efforts conducted in IBS so far, as 
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these are conducted in larger sample sizes than reported before and we have been able to use 
an hypothesis-free approach testing common genetic variation across the entire genome. 
These studies corroborate our hypothesis of general population-based cohorts to provide 
excellent opportunities for the study of the genetics of IBS, although our current sample size 
(1,335 IBS and 9,768 controls) still does not seem to be large enough in order to reach 
genome-wide significance. However, international collaboration and the launch of the 
bellygenes initiative (www.mdalab.org/bellygenes, PI Mauro D’Amato and co-PI Alexandra 
Zhernakova), hold promise to overcome this challenge. This project has been granted access 
to genotype and phenotype data from several large European general population-based 
cohorts and biobanks, and finally has enabled statistically well-powered and exceptionally 
large-scaled genetic studies (total target population >800,000 Europeans). In fact, as 
mentioned above, an important next step in our general-population approach very recently 
got accepted for publication (April 2018) in Gastroenterology; a GWAS of IBS utilizing data 
from the large UK Biobank cohort.239 In that study, self-reported doctor’s diagnosis of IBS 
was derived from questionnaires and a (finally sufficiently powered) GWAS was performed 
with more than 7 million high-quality SNPs in 9,576 IBS cases and 336,499 controls. A 
genome-wide significant association on chromosome 9 was identified (best p=3.57×10-8, 
SNP rs10512344). The same region has previously been linked to age at menarche, and 
interestingly a gender-stratified analysis revealed the IBS risk effect to be present only in 
women (p=4.29×10-10) but not in men (p=0.79). The IBS risk allele of rs10512344 also 
showed association with female IBS-C in clinical case-control samples from Europe and the 
US (p=0.015) and with harder stools in women from the PopCol cohort (p=0.0012). 
Moreover, an additional 13 loci of suggestive significance (p<5.0×10-6) were identified in the 
UK Biobank GWAS, and interestingly, gene-set enrichment analysis of candidate IBS risk 
genes linked to these loci suggest these genes to be significantly enriched in ion channel 
activity related pathways. This finding is intriguing, since even though an alternative 
definition of IBS was used in this study —self-reported doctor’s diagnosis in contrast to 
Rome criteria used in paper IV— the results from this study adds on to the emerging 
evidence (including that from paper IV) of a role of ion channels in IBS pathophysiology. In 
addition, it confirms the applicability of using large general-population based cohorts for the 
discovery of IBS risk genes and loci, and also open up for further investigation of gender 
specific effects in IBS.  
To conclude, in paper IV we conducted a meta-analysis combining five independent GWA 
studies of data from European epidemiological cohorts. We were able to include a total of 
1,335 IBS cases and 9,768 asymptomatic controls, and our results 1) demonstrate the 
feasibility of our alternative approach of using general population-based cohorts for the 
purpose of IBS gene discovery, 2) identify seven suggestive IBS risk loci that deserves 
attention in follow-up validation efforts, and 3) highlight ion channels and their activities as 
plausible biological pathways in IBS pathophysiology, which reinforces our previous 
observations and warrants further investigation. 
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5 CONCLUDING REMARKS AND FUTURE OUTLOOK 
In an attempt to shed light on the so far poorly understood functional GI disorder irritable 
bowel syndrome (IBS), the overall aim of the work presented here was to identify, validate 
and functionally characterize the genetic component of this condition, with the scope of this 
thesis mainly focusing on the discovery phase. IBS is a complex and heterogeneous 
phenotype that poses many challenges when trying to decipher its genetic background, and 
importantly, we believe that this is not simply one single condition, but a constellation of 
disorders with similar symptoms but possibly different underlying pathophysiological 
mechanisms. Therefore, different study approaches have been adopted depending on the 
specific hypotheses investigated.  
In paper I, using a candidate-gene approach, we report common genetic variation in the 
NPSR1 gene to influence the predisposition to recurrent abdominal pain (RAP) in Swedish 
children, possibly through altered expression levels. This gene encodes the receptor of 
neuropeptide S, a signaling peptide that appears to act along the brain-gut axis to regulate 
various functions including pain perception, inflammation, gut motility, sensation and 
secretion of gut hormones and neuropeptides. The exact role of NPSR1 and its ligand in RAP 
and IBS is not known and further investigation is warranted. 
While IBS appears to be multifactorial and polygenic in most cases, also smaller subsets of 
patients seem to exist, for whom single-gene abnormalities have high penetrance on disease 
risk and may principally account for most of their GI symptoms. A perfect example of this is 
the SCN5A gene, an ion channel gene involved in the generation of slow waves underlying 
motility patterns in the gut; 2.2% of IBS patients carry functionally disruptive SCN5A gene 
mutations.56 This observation led us to investigate also other ion channel genes of potential 
relevance for IBS. In paper II, by inspecting association data from our previously published 
GWAS of IBS180 at genetic locations for 27 ion channel genes, we could provide evidence of 
an association with the transient receptor potential cation channel gene TRPM8 (the ‘cold and 
menthol receptor’). Polymorphisms in this gene showed nominal significance in the GWAS 
data and were significantly replicated in an independent Swedish multicenter sample where 
the genetic effect appeared to be specific to constipation. Confirmatory, risk alleles also 
correlated with harder stool consistency in a general population cohort. Thus, paper II 
provides evidence for an association of the ion channel gene TRPM8 in IBS and constipation. 
The findings warrant further investigation, and the TRPM8 gene represents an ideal candidate 
for future sequencing efforts in IBS to evaluate the potential relevance of also rare variants.  
Dietary carbohydrates are recognized in many IBS sufferers as symptom triggers, and 
avoidance of specific foods perceived as problematic is common. Interestingly, >50% of 
1,242 IBS patients completing a survey in the US in 2007 believed IBS is a result of “Lack of 
digestion enzymes”.118 This was a priori designated a misconception, but in paper III we 
provide evidence of a role of sucrase-isomaltase (SI) genetic variation in IBS. The findings 
suggest milder forms of SI deficiency may be present in a subset of IBS patients, and in 
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addition to rare heterozygous mutations, we demonstrated a role of a common coding 
polymorphism, which significantly associates with increased risk of diarrhea-predominant 
IBS phenotypes, and is functionally relevant with 35% reduced enzymatic activity. Hence, 
genetically derived SI deficiency may explain the link between food ingestion and IBS-like 
symptoms in a subset of patients. If these patients can be identified, dietary modifications 
and/or enzyme replacement therapies are available for their symptom management.  
Finally, in paper IV we conducted a meta-analysis combining five independent European 
GWA studies including a total of 1,335 IBS cases and 9,768 asymptomatic controls. This 
study represents an important step in our general population-based approach (described in 
1.5.5); a ‘thinking outside the box’ strategy for the discovery of IBS risk genes and variants 
by taking advantage of the high prevalence of IBS in the general population and the extensive 
amount of genotype and phenotype data available in large epidemiological cohorts. Although 
no genome-wide significant association was observed in our study, we identified seven 
suggestive IBS risk loci and highlighted ion channel activities as plausible biological 
pathways implicated in IBS. This study demonstrates the feasibility of the general population-
based approach for the purpose of IBS gene discovery, providing a first solid foundation for 
similar efforts in even larger sample sizes. Through international collaboration and the 
bellygenes initiative that we coordinate (www.mdalab.org/bellygenes), a critical mass of 
general and dedicated resources has finally been gathered, including large European 
population-based cohorts/biobanks (UK Biobank, LifeLines, EGCUT, HUNT and others) and 
clinical case-controls from European/US tertiary centers, now enabling very large-scale 
genetic studies of IBS. These studies are ongoing, and excitingly, one of them just got 
published (available online on April 5th 2018).239 In that study, data was utilized from the UK 
Biobank for 346,075 individuals (including 9,576 cases with self-reported doctors’ diagnosis 
of IBS), representing the largest GWAS effort in IBS to date. A genome-wide significant 
signal was detected that had a strong effect on IBS risk in women only, and once again, post-
GWAS in silico analyses of the genes linked to suggested IBS risk loci suggested ion channel 
activities to be implicated in IBS, this despite the alternative IBS definition used (self-
reported diagnosis, in contrast to Rome III in paper IV).  
In future efforts, large-scale well-powered studies hold promise to finally identify 
unequivocal risk loci in IBS. Findings coming from these efforts then need to be validated 
through replication in well-characterized IBS cases with a clinical diagnosis from specialized 
clinics and asymptomatic controls, and genes/variants also functionally characterized for their 
role in IBS. In addition, the use of alternative definitions and intermediate phenotypes of IBS 
will provide important information, and one should also strive to evaluate subtype and gender 
specific effects across different populations. To identify subgroups of patients where rare 
variants/mutations in single genes may be responsible for their IBS symptoms, sequencing of 
specific genes in well-selected cases and controls is necessary, and eventually even next-
generation sequencing efforts of the entire exome or genome. Finally, although challenging, 
gene-gene interactions and their interplay with environmental factors will eventually need to 
be clarified as complex traits such as IBS result from a combination of ‘nature and nurture’.  
   52 
A major take-home message from this thesis is that several pieces of evidence now coming 
from different studies/approaches (including the studies on SCN5A,56 TRPM8/paper II, 
GWASs of IBS defined by Rome III criteria/paper IV, GWAS of stool frequency,84 and the 
recent GWAS of self-reported IBS in the UK Biobank)239 clearly point to a role of ion 
channels and their activities in IBS. This warrants further investigation and may be of 
particular importance for therapeutic exploitation, as the accessibility of ion channels on the 
cell surface makes them attractive drug targets. Novel therapeutics may be developed, but 
also available agents targeting specific ion channels could be exploited for the purpose of 
treatment in IBS subgroups. Examples of this already exist, for instance with mexiletine, an 
anti-arrhythmic drug targeting the NaV1.5 channel, which improved stool frequency in a 
severely constipated patient carrying a loss-of-function SCN5A mutation in a proof-of-
principle study.56 Following up on paper II, it may also be interesting to (re)evaluate the 
effect of peppermint oil on symptom improvement in IBS-C, and investigate potential 
pharmacogenetic effects, i.e., differences in response based on patients’ TRPM8 genotype.  
IBS is a perfect example of a group of patients where targeted research towards 
individualized medicine will be of great importance. Research on IBS pathophysiology has 
provided an overall picture of various factors involved, with IBS summarized as a disorder of 
gut-brain interaction.53 However, the etiology and mechanisms in this picture is still far from 
clear. A better insight into the genetic background of IBS will be of great help, not only to 
understand more of the involved mechanisms and pathways, but also to identify therapeutic 
targets, and importantly, contribute to the re-classification of IBS into novel subtypes 
(integrating different layers of data including genetic variation) based on molecular patterns 
and an underlying biology rather than the clinical symptomatology. Although IBS is not a 
‘dangerous’ condition, it is still serious, and often chronic, difficult to treat and reduces 
quality of life for a substantial proportion of the general population. With an estimated 
worldwide IBS prevalence of around 10%, this corresponds to remarkably 33 million affected 
people in the US alone, and 74 million in Europe. Thus, as an example of the significance of 
genetic studies in IBS, if or when a small portion of this condition can be explained by a 
genetically derived dysfunction, like for instance SI deficiency or NaV1.5 ion channelopathies 
in at least 2% of patients, then this will have implications for as many as 650,000 people in 
the US and almost 1.5 million people in Europe, including ~20,000 in Sweden. 
To conclude, it is a long, winding and challenging road to the identification of unequivocal 
IBS risk genes and variants. However, I believe the studies presented in this thesis represent 
an important step in the right direction, moving towards an improved knowledge of IBS 
pathophysiology at the molecular level. As we learn more about its genetic background we 
will be able to distinguish underlying conditions now gathered under the same ‘umbrella’ of 
IBS and contribute to a better understanding of the etiology behind IBS symptoms. The 
results from these and future efforts are expected to contribute to patient stratification and 
improved diagnostic and therapeutic management in a more individualized manner.  
 
   53 
6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Vad är IBS? Irritable bowel syndrome (IBS), colon irritabile, känslig tarm eller stressmage,  
—ja, kärt barn har många namn—, är idag den vanligaste typen av funktionella magtarm-
besvär och drabbar mer än 10 % av befolkningen. Magbesvären är vanligare hos kvinnor än 
män och yttrar sig som återkommande smärta eller obehag i nedre delen av buken och 
avföringsrubbningar såsom diarréer (IBS-D, diarrhea), förstoppning (IBS-C, constipation) 
eller en kombination av både och (IBS-M, mixed) (bild 1, sid. 2). Uppblåsthet och gasighet är 
också vanligt. Termen funktionell betyder i detta fall att en medicinsk undersökning inte kan 
ge någon organisk eller strukturell förklaring till magbesvären (exempelvis en inflammation 
eller skada i tarmen) och det finns i nuläget inga biologiska markörer eller specifika tester för 
att fastställa IBS. Därför används istället symptom-kriterier (s.k. Rome-kriterier) för 
diagnosticering, i kombination med uteslutning av andra potentiella orsaker som kan yttra sig 
med liknande symptom, såsom glutenintolerans eller inflammatorisk magtarmsjukdom.  
Vad vet vi om orsaken? Ett ökat forskningsintresse inom IBS har gjort att vi nu har en 
uppfattning om många olika faktorer som verkar spela roll i dess bakomliggande 
patofysiologi (sjukdomsmekanismer), bland annat psykosociala aspekter, tarmfloran, 
funktioner av tarmens egna muskler, immunsystem och nervsystem, samt dess 
kommunikation med hjärnan. En översiktlig bild av dessa säger oss att samspelet mellan 
hjärna och tarm av någon anledning är ur balans, och IBS kallas därför även för en disorder 
of gut-brain interaction (bild 3, sid. 10). Trots detta är etiologin (orsaken) bakom IBS 
fortfarande oklar och verkar kunna variera från individ till individ, så det finns tyvärr inget 
generellt botemedel, utan behandlingen är symptombaserad och individuell där patienten får 
testa sig fram. Detta gör att livskvalitén ofta är markant försämrad hos en person med IBS. 
Det finns även en stark koppling till stress, depression, andra typer av psykologiska och 
smärtrelaterade tillstånd, samt andra funktionella magtarmsjukdomar, och frånvaro från 
jobb/skola på grund av IBS är extremt vanligt. Därför är IBS, trots att det i sig inte är en farlig 
sjukdom, ändå ett mycket allvarligt problem, både för de drabbade men även för samhället 
och sjukvården då det orsakar höga socioekonomiska kostnader. Av denna anledning är det 
viktigt att vi försöker ta reda på mer om orsakerna till IBS, så att vi bättre kan förstå vilka 
som drabbas och varför, och hur vi kan förebygga och behandla det.  
Varför studera genetiken bakom IBS? Flera studier har bekräftat att IBS har en ärftlig faktor 
och liksom många andra vanliga komplexa (multifaktoriella) sjukdomar så avgör en 
kombination av genetik och miljö vem som blir sjuk och på vilket sätt. I varje cell i kroppen 
finns en enorm uppsättning livsviktig och unik information (DNA) och tack vare att ca 0,1 % 
av denna ”instruktionsbok” är olika mellan två personer så har vi möjlighet att jämföra dessa 
genetiska variationer mellan sjuka och friska och på så sätt skaffa oss kunskap om vilka gener 
och varianter som påverkar risken för en viss sjukdom. Genom att kartlägga detta får vi bättre 
insikt i vilka processer och funktioner i kroppen som är involverade, och kan även identifiera 
tänkbara mål att rikta läkemedel mot. Målet för genetiska studier inom IBS är även att bidra 
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till bättre diagnostik och tydligare (ny) klassificering av sjukdomen för att kunna stratifiera 
patienter och möjliggöra mer individanpassade behandlingar och rekommendationer.  
Hur ser den genetiska bakgrunden av IBS ut? Genetiska studier av många andra sjukdomar 
har lyckats väl och gett användbar information, men tyvärr ligger IBS-forskningen i detta 
område en bra bit efter. Flertalet riskgener har föreslagits i studier men än så länge, möjligtvis 
med ett (TNFSF15) eller ett fåtal undantag, finns inga övertygande evidens för dessa geners 
roll i IBS. En diffus och osäker definition av IBS, svårigheter att tydligt kunna mäta och veta 
vem som är drabbad, samt otillräckligt med fall-kontroll-studier från gastro-mottagningar gör 
att genetikforskning inom IBS är mycket utmanande. Dessutom är vi som forskar inom detta 
område övertygade om att IBS inte bara är en sjukdom utan snarare en mix av olika typer av 
tillstånd med olika underliggande orsaker trots liknande symptom. För de flesta IBS-patienter 
är patofysiologin multifaktoriell där flertalet faktorer i olika kombinationer spelar roll, men 
evidens pekar även mot att det finns vissa undergrupper av patienter där enstaka faktorer 
verkar kunna orsaka deras IBS-symptom. På liknande sätt ser den genetiska arkitekturen ut 
att vara ett polygent tillstånd för de flesta patienter, där många vanligt förekommande 
genetiska varianter —var och en med relativt liten påverkan på sjukdomen— tillsammans 
bidrar till att IBS utvecklas. Samtidigt verkar det finnas mindre subgrupper av patienter där 
mer sällsynta varianter (mutationer) i en eller flera specifika gener —dock med högt 
inflytande på risken för IBS— istället kan förklara huvuddelen av symptomen (bild 5, sid. 
20). Därav behövs olika typer av strategier för att studera genetiken bakom IBS, alltifrån 
hypotesdrivna kandidatgen-studier till stora genomvida associationsstudier (GWAS).  
Vad innehåller denna avhandling? Mitt doktorandprojekt har handlat om att identifiera, 
validera och studera funktionen av genetiska faktorer som bidrar till IBS, med den största 
tonvikten på identifiering. Nedan följer en kort beskrivning av de fyra ingående artiklarna i 
denna avhandling samt vad vi huvudsakligen kommit fram till i dessa studier.  
Artikel I är en kandidatgen-studie där vi såg att genetisk variation (”snippar”; SNPs, single 
nucleotide polymorphisms) i genen NPSR1 ökar risken för återkommande funktionell 
buksmärta hos 12-åriga barn (n=1 741) från en svensk födelsekohort (BAMSE). Denna gen 
kodar för en receptor till neuropeptid S —en signalsubstans som verkar vara involverad i 
flertalet funktioner i brain-gut axis, såsom reglering av oro och stress, inflammation, 
tarmmotorik och uppfattning av smärta. Ingen av de associerade SNP:arna orsakar någon 
förändring av själva aminosyrasekvensen i proteinet, men eftersom de är lokaliserade i början 
av genen så skulle de kunna påverka själva uttrycket av receptorn, vilket genuttrycksdata 
tillgänglig online även indikerade. På vilket sätt detta påverkar buksmärtan är dock oklar, 
men skulle kunna ha att göra med låggradig inflammation i tarmen, utsöndring av olika 
magtarmhormoner och neuropeptider, eller en direkt inverkan på hur hjärnan reglerar 
inkommande smärtsignaler (bild 9, sid. 36). Vidare studier behövs för att utreda detta.  
Idén till artikel II är baserad på en tidigare studie från vår forskningsgrupp i samarbete med 
forskare på Mayo Clinic i USA, där mutationer i genen SCN5A hittades i 2,2 % av IBS-
patienter men inte hos någon av de friska kontrollerna.56 SCN5A kodar för en jonkanal som 
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inte bara har roll i pacemakerfunktionen i hjärtat utan även för motoriken i magtarmkanalen. 
Vi hypotiserade då att även andra jonkanaler relevanta för magtarmfunktioner skulle kunna 
ha en roll i IBS. I artikel II sökte vi därför först igenom resultaten från vår tidigare 
publicerade GWAS av IBS180 och gick sedan vidare med fyra gener som visade association i 
GWAS-datan och genotypade SNP:ar från dessa gener i 386 IBS-patienter och 357 kontroller 
rekryterade från olika gastro-mottagningar runt om i Sverige. Flertalet SNP:ar i en av 
generna, TRPM8, visade signifikant association med IBS i denna replikationsstudie. Effekten 
var specifik för förstoppnings-relaterad IBS, och riskalleler korrelerade även med hårdare 
avföring i ett separat dataset (svenska studien PopCol). TRPM8 är en jonkanal som 
stimuleras av kall temperatur och bl.a. mentol, och verkar på olika sätt vara involverad i 
uppfattningen av både kyla och smärta. Den tycks även kunna interagera med andra typer av 
jonkanaler (bild 10, sid. 38). Intressant nog har pepparmyntsolja (rik på mentol) visats ha 
muskelrelaxerande och smärtlindrande effekt för IBS-patienter, även om mekanismen för 
detta är oklar. Artikel II visar att SNP:ar i TRPM8-genen påverkar risken för IBS och 
förstoppning. I framtida studier vore det spännande att utreda om även sällsynta variationer 
(mutationer) har betydelse för IBS hos vissa patienter (såsom i fallet med SCN5A-genen). 
Artikel III handlar om en helt annan aspekt av IBS; spjälkning av kolhydrater. Kopplingen 
till mat i IBS är omöjlig att undgå; de flesta drabbade anser att olika livsmedel triggar deras 
symptom, vilka ofta uppstår eller förvärras efter en måltid, och det är mycket vanligt att 
undvika livsmedel som uppfattas som problematiska. Kolhydrater som ej absorberas i tarmen 
har en förmåga att dra åt sig vatten genom osmos, och fermenteras ofta av tarmbakterier i 
tjocktarmen varpå gaser bildas. Hos vissa kan detta orsaka diarré, utspänd tarm och obehag 
eller smärta. Samma sak sker exempelvis hos laktosintoleranta personer, men även i andra 
mer ovanliga tillstånd av enzymbrist, så som kongenital sukras-isomaltas(SI)-brist (bild 11, 
sid. 40). Detta är en medfödd sjukdom som beror på nedärvda mutationer i SI-genen (kodar 
för både sukras och isomaltas som sitter ihop i ett enzymkomplex) och orsakar malabsorption 
av socker och stärkelse eftersom dessa inte kan brytas ner ordentligt i tunntarmen. Den 
klassiska formen av SI-brist upptäcks i tidig ålder men mildare former verkar existera och 
diagnosen har även satts senare i livet. Detta tyder på att vissa former potentiellt är “gömda” 
inom IBS och i artikel III undersökte vi därför om SI-mutationer och/eller funktionella 
SNP:ar är av relevans för IBS. Först sekvenserades SI-genen i personer med IBS-D från fyra 
familjer. Då hittades ingen mutation men däremot en intressant SNP (p.Val15Phe) som 
ändrar aminosyran valin till fenylalanin i den region av molekylen som sitter förankrad i 
cellmembranet. 15Phe-varianten verkar kunna försämra funktionen av enzymen och detta 
bekräftades med experiment in vitro som bl.a. visade 35 % minskad enzymaktivitet jämfört 
med 15Val. Genom att genotypa denna SNP tillsammans med fyra SI-mutationer (de 
vanligast förekommande i kongenital SI-brist) i 1 031 IBS-patienter och 856 friska kontroller 
från Europa och USA, såg vi att mutationerna är vanligare hos IBS än hos kontroller och 
p.Val15Phe starkt associerat med risk för IBS, speciellt diarré-relaterad (bild 12, sid. 42). 
Risk-allelen 15Phe korrelerade även med ökad avföringsfrekvens och tarmflorans 
sammansättning i data från PopCol. Resultaten från denna studie stärker alltså hypotesen om 
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att SI-brist verkar finnas i ett spektrum från allvarligare till mildare former, och att vissa 
patienter med IBS-symptom i själva verket har en mildare variant av denna enzymbrist.  
Artikel IV representerar ett viktigt steg i en speciell approach vi har för att leta efter IBS-
riskgener; användning av data från stora populationsbaserade biobanker och epidemiologiska 
kohorter för att utföra GWAS-studier (en genetisk strategi som söker efter DNA-variationer i 
hela genomet) och dess meta-analyser. Därmed kan vi uppnå betydligt större studiestorlek 
och statistisk power än vad man hittills lyckats med inom IBS. Innan mitt doktorandprojekt 
hade inga GWAS-studier utförts av IBS, men strax efter att jag registrerades publicerade 
gruppen den första —en pilotstudie med data från en stor svensk tvilling-kohort (TwinGene, 
en del av det svenska tvillingregistret).180 Artikel IV är en uppföljning av denna pilot-
GWAS, där vi nu utfört fem GWAS:er av IBS i olika epidemiologiska kohorter från Europa 
(inklusive TwinGene) och sedan kombinerat resultaten i en stor meta-analys av totalt 1 335 
IBS-fall och 9 768 asymtomatiska kontroller. Även om inga associationer kunde identifieras 
på s.k. genomvid signifikansnivå (p≤ 5.0×10-8) hittade vi sju DNA-regioner som eventuellt 
kan kopplas till IBS-risk (p≤ 5.0×10-6) (bild 15 och 16, sid. 47, 48). Intressant nog verkar 
många av generna i dessa regioner koda för jonkanaler eller vara involverade i processer som 
rör dess aktivitet. Jonkanaler och dess funktioner har i flera andra studier kopplats till IBS, 
bl.a. SCN5A,56 TRPM8/artikel II, den första GWAS:en av avföringsfrekvens,84 och dessutom 
i en mycket nyligen publicerad GWAS av självrapporterad IBS i en betydligt större 
studiepopulation (9 576 fall och >300 000 kontroller från UK Biobank) utförd av vår 
forskargrupp.239 Dessa studier tillsammans pekar mot att jonkanaler är viktiga i IBS, och 
motiverar till fortsatta utredningar av dess specifika roller för magtarmsymptom. Denna 
kunskap är lovande för framtida behandling eftersom jonkanalerna ofta sitter förankrade i 
cellmembran väl nåbara för läkemedel, och det finns redan exempel på när redan tillgängliga 
läkemedel använts i IBS för att modifiera dessa jonkanalers aktivitet. Artikel IV 
demonstrerar även att vår populations-baserade strategi verkar lovande och fortsatta liknande 
studier men i betydligt större studiepopulationer är nu genomförbara tack vare internationella 
samarbeten och vårat bellygenes initiative-projekt (www.mdalab.org/bellygenes) där en 
avsevärd mängd genotyp- och fenotypdata har samlats ihop både från den generella 
populationen (stora epidemiologiska kohorter/ biobanker) och från gastro-mottagningar (fall 
och kontroller för validering och replikationsstudier).  
För att sammanfatta så är det en lång och utmanande väg att vandra för att lyckas hitta IBS-
riskgener och dess varianter, men jag är övertygad om att studierna i denna avhandling är ett 
viktigt steg i rätt riktning. Denna och fortsatt forskning ger oss bättre kunskap om vad det 
egentligen är vi kallar IBS, och bidrar även till identifiering av specifika underliggande 
orsaker hos olika mindre subgrupper av de som nu samlas under samma ’tak’. Detta kommer 
att leda till förbättrad diagnosticering och klassificering, samt mer individ-anpassade 
behandlings-strategier. Dessa framsteg kommer vara otroligt viktiga eftersom även om en 
liten del, säg 2 %, av IBS-patienterna kan identifieras och korrekt behandlas, så motsvarar det 
(förutsatt att prevalensen av IBS är 10 %) så många som 650 000 människor i USA och 
nästan 1,5 miljoner i Europa, varav ~20 000 i vårt lilla Sverige, som skulle kunna bli hjälpta. 
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